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ABSTRACT 
Atherosclerosis is thought to be mediated by immune response in which oxidized low 
density lipoprotein (OxLDL) is one of the major antigens. The exact linkage between 
anti-OxLDL antibodies and atherosclerosis, however, is controversial. One of the 
sources of this controversy is the inherently heterogeneous and complex nature of 
OxLDL as an antigen. This study aims to identify and characterise a new type of 
structurally definable surrogate antigen for OxLDL for use in serologic assays. 
 
The study applied two techniques for cloning antibodies. The first step was the 
generation of a monoclonal anti-OxLDL antibody, designated LO-1, by fusing mouse 
B cells and myeloma cells. The mouse used in this fusion was not immunized but fed 
with high fat diet to reflect the physiologic but hyperlipidemic immune environment. 
The second step was to use a phage display system (Tomlinson library of single chain 
variable antibody fragments) to screen anti-idiotypic antibodies (anti-id) against an 
anti-OxLDL monoclonal antibody generated from that mouse. The anti-id selected for 
further characterisation, was designated H3.  This anti-id, which probably mimics 
both peptide and lipid components of OxLDL, was used as an antigen in a serologic 
assay (both in mice and humans) and compared with ordinary OxLDL antigens 
conventionally used by earlier researchers. Titres of antibodies against H3 correlated 
well with antibodies against malondialdehyde-conjugated LDL. Although the overall 
performance of anti-H3 antibodies was no better than conventional anti-OxLDL 
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assays in predicting atherosclerosis, they showed an inverse relationship with the 
extent of left anterior descending coronary artery stenosis in patients with established 
coronary artery disease. 
 
This project has developed a novel approach to measuring OxLDL antibodies. The 
proposed unique mimicry of both the lipoprotein and the phospholipid components of 
OxLDL may reveal a functionally significant epitope of OxLDL that has not been 
successfully mapped by previously reported methodologies. The novel anti-id H3 and 
the corresponding mimetic region of OxLDL therefore provide new insight and new 
tools for future research on the humoral response related to atherosclerosis.  
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CHAPTER 1 Introduction 
1.1 Problem statement 
Atherosclerosis, the major cause of cardiovascular diseases (CVD), is a chronic 
disease that starts in the adolescence, accelerates through adulthood, and then 
intensifies in old age. Advanced atherosclerotic lesions have been found in autopsies 
of young and asymptomatic individuals and also in live individuals by the utilization 
of intra-coronary ultrasound. Therefore, a better understanding of and better 
diagnostic tools capable of detecting early atherogenesis are necessary for 
practitioners to provide patients with more timely intervention to delay the onset, to 
slow the course and the development, and to moderate the severity of clinical 
symptoms. 
 
There is plenty of evidence to show that immune and inflammatory processes are 
important both in triggering and enhancing atheroma formation and plaque rupture 
(Ross, 1999). Several immunogens such as oxidized low density lipoprotein (OxLDL) 
and heat shock proteins have been hypothesized as relevant in the atherosclerosis 
process. Many previous studies have tried to use various OxLDL-related 
inflammatory molecules as markers of the disease or tools for the study of its 
pathogenesis. One of the most commonly proposed mediators are antibodies against 
OxLDL. However, the results of innumerable previous clinical studies have been 
inconsistent and even outright contradictory. Although humoral immune responses to 
OxLDL have been a subject of intense study by many researchers for a long time, 
there is still little agreement as to their exact role in atherogenesis. Some studies have 
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propose that anti-OxLDL antibodies are atherogenic while others state that these 
antibodies are atheroprotective (Shoenfeld, et al., 2004). The apparent lack of 
consistency among these reports is attributable at least in part to the diverse study 
designs, study populations, and clinical and laboratory end points. Most importantly, 
however, the heterogeneity is caused by OxLDL being a large, complex, and highly 
variable particle, and inconsistencies which have been caused by a lack of a 
standardised methodology for defining specific and functional epitopes. 
 
1.2 The aim and scope of the study 
The aim of my project was to generate a structurally-defined antigen surrogate that 
can substitute for a functional epitope of OxLDL. We planned for this antigen to be 
readily duplicable and suitable for a more standardized and reproducible assay which 
future studies could use for researching humoral response against OxLDL in mice and 
human. Additionally, I aimed for this assay to further define and clarify the 
correlation between anti-OxLDL antibodies and atherosclerosis. 
 
This project utilised two techniques of generating monoclonal antibodies, namely 
hybridoma fusion and phage display, and the project used the antibody products in 
mice models and human serum samples. The demographic and biological parameters 
analysed in this thesis were chosen to be relevant to atherosclerosis. 
 
1.3 The structure of this thesis  
The present knowledge on immune interactions to atherosclerosis is reviewed briefly 
in Chapter 2, which focuses mainly on the generation and pathological effects of 
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modified LDL and antibodies against it. The signal pathways by which OxLDL 
activates cells are also discussed. Numerous clinical studies that revealed 
contradicting relationships between anti-OxLDL antibodies and atherosclerosis are 
listed in three tables according to their conclusions on whether anti-OxLDL 
antibodies and atherosclerosis have negative, positive, or no correlations. 
 
Chapter 3 describes the generation and characterization of a novel monoclonal anti-
OxLDL antibody by fusing B cells of LDLr(-/-) mice and myeloma cells. 
 
Chapter 4 depicts the selection of anti-idiotype (anti-id) antibodies against the above-
mentioned monoclonal anti-OxLDL antibody. A human single-chain variable 
fragment (scFv) phage library was used in the selection. The sequences of anti-id(s) 
were compared with apoB protein within LDL.   
 
The various serological assays of modified LDL, phosphocholine, and anti-id in mice 
are reported in chapter 5. The chapter also analyzes the correlations between these 
assays and demographic parameters. Most importantly, the association between 
assays made with usual OxLDL antigens and with anti-id is examined at the end of 
this chapter. 
 
Chapter 6 repeats chapter 5 and establishes a similar correlation, but with human sera.  
This chapter also thoroughly examines the relationship between serological assays 
and atherosclerosis-related parameters.  
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Chapter 7 provides the final synthesis and discussion. It also suggests some 
theoretical implications, practical applications, and areas for further investigation. 
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CHAPTER 2 Background 
2.1 Chapter Introduction 
The current knowledge in the immune aspects of the complex relationship between 
atherosclerosis and OxLDL will be described in this chapter. Section 2.2 is an overall 
review of atherosclerosis as a chronic immunity-related inflammatory disease. Then 
section 2.3 focuses on the key antigen of atherosclerosis: OxLDL, whose structure, 
generation, and possible effects on atherosclerosis are summarized. Section 2.4 
reviews the current knowledge of the roles and functions of anti-OxLDL antibodies in 
atherosclerosis. The final section, 2.5, introduces some potential representative 
material of OxLDL. 
 
2.2 Atherosclerosis is a chronic immune-mediated inflammatory disease 
Atherosclerosis is a complex disease, and many risk factors have been identified such 
as hypercholesterolemia, hypertension, diabetes, age, male gender, and smoking. 
There is convincing evidence supporting the view that atherosclerosis is an 
inflammatory process involving both innate and adaptive immune systems (Hansson, 
2005) (Hansson, Robertson, et al., 2006).  
 
Both cellular and humoral components of immune response participate in 
atherogenesis (Sherer & Shoenfeld, 2006). Macrophages, T cells, autoantigens, 
autoantibodies, complement, chemokines, and cytokines orchestrate as a complex 
network that triggers and regulates the disease (Frangogiannis, et al., 2002).  
 
 21 
2.2.1 Cellular immunity 
Atherosclerosis is initiated by the accumulation and modification of cholesterol-
containing LDL in the arterial intima.  Monocyte and macrophages are the key 
effector cells, whilst T cells activate and control the inflammatory process via various 
cytokines, enzymes and cell surface molecules (Hansson, 2005; Packard, et al., 2009). 
 
The recruitment of monocyte into the arterial wall is crucial for atheroma formation. 
In the early stage of atherosclerosis, activated endothelial cells express adhesion 
molecules such as P-selectin and vascular cell adhesion molecule-1 (VCAM-1), 
leading to the capture of leukocyte from flowing blood, adhesion and transmigration 
into the sub-endothelial space (Rao, et al., 2007). Endothelial activation and leukocyte 
migration are triggered mainly by OxLDL and locally secreted cytokines and 
chemokines, including monocyte chemoattractant protein-1 (MCP-1) (Berliner, et al., 
2001). Monocytes mature into macrophages in the intima and express scavenger 
receptors under the influence of macrophage colony-stimulating factor (M-CSF). The 
scavenger receptors involved in atherosclerosis include CD36, CD68, scavenger 
receptor (SR)-A, SR-B, CXCL16, and lectin-type oxidized low-density lipoprotein 
receptor 1 (LOX1) (Packard, et al., 2009). Expression of toll-like receptors (TLRs), in 
particular TLR2 and TLR4, is also enhanced by M-CSF and these receptors mediate 
signalling following simple pattern-recognition and a subsequent inflammatory 
cascade.  
 
T cells, especially with T helper-1 (Th1) function, also enter the arterial wall and are 
reported to promote local inflammation and the growth of plaque (Hansson & Libby, 
2006) (Packard, et al., 2009). The function of T helper-2 (Th2) seems to be more 
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puzzling and dependent on the stage of disease (Nilsson & Hansson, 2008). 
Regulatory T-cells might control lesion development and progression by the secretion 
of cytokines IL-10 and TGFβ (Mallat, et al., 2007).  
 
Many other leukocytes, including mast cells, natural killer cells, dendritic cells, and 
probably neutrophils, also contribute to atherosclerosis by various complex 
mechanisms (Packard, et al., 2009).   
 
2.2.2 Humoral Immunity 
In addition to these cellular components, many humoral immune factors such as 
complement, antibodies, cytokines, and chemokines have also been shown to play 
important roles in the regulation of atherosclerosis in mice. 
 
Deposition of C3 and C4 is found in atherosclerotic lesions. Rabbits deficient in C6 
are protected from atherosclerosis (Schmiedt, et al., 1998). On the other hand, the 
atherosclerosis lesion size is increased in LDLr-/- mice deficient in an upstream 
complement protein, C1q (Bhatia, et al., 2007). This apparent discrepancy indicates 
that the complement system may play different roles at different stages of 
atherogenesis (Haskard, et al., 2008).  
 
Besides complement, antibodies also actively regulate atherosclerosis. B cells provide 
atheroprotection in mouse models (Caligiuri, et al., 2002; Major, et al., 2002). 
Furthermore, antibodies that react to OxLDL particles are found in both human 
disease and mouse models of atherosclerosis (Shaw, et al., 2000). 
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Cytokines are classified as either pro-inflammatory (e.g. interferon-γ and TNFα) or 
anti-inflammatory (e.g. IL-10 and TGF-β). Various leukocyte adhesion molecules and 
cytokines aid the further recruitment of monocyte-macrophages. These macrophages 
phagocytose OxLDL, leading to the formation of foam cells. 
 
2.3 OxLDL is the key antigen in atherosclerosis 
Among many proposed autoantigens in atherosclerosis, OxLDL has been the most 
studied. Other frequently mentioned antigens include heat shock proteins, β2 
glycoprotein I, and apoptotic cells (Binder & Silverman, 2005)  (Nilsson, et al., 2008). 
Under oxidative stress, both the lipid and protein components of LDL are easily 
oxidized (Itabe, 2009). The exact mechanisms by which LDL is oxidised are not yet 
clearly known. Nevertheless, OxLDL can be found in atherosclerosis plaque at all 
stages of atherosclerosis and is thought to be critical in atherogenesis. The structure 
and possible pathological and immunogenic roles of OxLDL are discussed in this 
section.  
 
2.3.1 The structure and function of LDL 
LDL is an extremely complex and large molecule (18 to 25 nm in diameter). It is 
composed of a hydrophobic core of triglycerides (170 molecules) and cholesterol 
ester (1600 molecules), surrounded by a shell of 700 molecules of phospholipids and 
a single apolipoprotein apoB-100 molecule. ApoB100, the only protein component of 
LDL, consists of 4,536 amino acid residues and with a molecular weight of 550 kDa. 
It constitutes about 20% of a whole LDL particle by weight (Mertens & Holvoet, 
2001).  The dynamic between the two key surface components (phospholipid shell 
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and apoB-100) results in a highly heterogeneous and complex structure (Segrest, et 
al., 2001).  
 
The primary function of LDL is to transport lipid (mainly cholesterol) in circulation. 
This is essential for supplying cholesterol to cells and tissues for homeostatic 
purposes. Several specific receptors such as classical apoB/apoE receptors and 
scavenger receptors regulate the cellular intake of LDL, which is dependent on the 
structure of LDL and conformation of apoB 100 (Prassl & Laggner, 2009).  
 
2.3.2 The oxidation of LDL 
LDL is subject to various post-secretory modifications, of which oxidation is the most 
thoroughly studied. Most components of LDL, including cholesterol, fatty acid, 
phospholipids and aopB100, can be oxidised. LDL may be oxidized by metal ions, 
reactive oxygen species, and various enzymes, of which lipoxygenases and 
myeloperoxidase are examples. Modification of LDL might occur in several phases: 
1) initiation (during which endogenous antioxidants are consumed), 2) propagation 
(when unsaturated fatty acids are oxidized to lipid peroxides), 3) decomposition 
(reactive aldehydes, i.e., malondialdehyde (MDA) and 4-hydroxynonenal are formed), 
and 4) adduction of these aldehydes to lysine residues of apoB (Mertens and Holvoet, 
2001). 
 
Researchers have attempted to mimic in vivo LDL modifications with different in 
vitro models, many of which use copper ion and MDA. However, these approaches 
carry with them a well known limitation: the oxidation of LDL is unlikely to be due 
solely to extensive MDA or metal ion-induced modification. Other factors are likely 
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to also contribute to such oxidation in vivo. An alternative approach is cell-related 
enzymatic digestion, which is thought to be more physiological (Mertens and 
Holvoet, 2001). Furthermore, it is a challenge to monitor the extent and nature of 
LDL oxidation. Some methods currently employed to estimate the modification of 
LDL include electrophoresis (which detects changes in charge and size), measurement 
of thiobarbituric acid reactive substances (TBARS), lipid peroxides, conjugated 
dienes, aldehyde, and fluorescent compounds formation (M F Lopes-Virella, et al., 
2000). 
 
The real antigenic epitopes for OxLDL, however, have been a subject of controversy 
for decades. Palinski and colleagues have proposed several oxidation-specific neo-
epitopes (Palinski, et al., 1990) (Palinski, et al., 1996). The peroxidation of the 
polyunsaturated fatty acids on the surface of phospholipid initiates the LDL oxidation 
process. This results in the formation of a range of highly reactive and immunogenic 
products (Binder, Shaw, et al., 2005) (Matsuura, et al., 2008).  
 
The origin of OxLDL in vivo is also largely unknown. Some observations hint that the 
vascular wall or atherosclerotic lesions could be primary sources of the circulating 
OxLDL: 1) abundant antioxidant in plasma prevents most oxidative events, 2) major 
cell types found in plaques (macrophages, monocytes, lymphocytes, smooth muscle 
cells, and endothelial cells) can accelerate the modification of LDL, 3) OxLDL have 
been detected in atherosclerotic lesions, and 4) small and dense LDL is more 
susceptible to oxidation and more atherogenic than large LDL. The smaller sizes of 
LDL particles may enable the particles to enter vessel walls more easily (Verhoye & 
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Langlois, 2009). These indirect considerations, however, are not sufficiently strong to 
allow us to conclude that the vascular wall is the major source of OxLDL. 
 
2.3.3 The atherogenic effects of OxLDL  
OxLDL triggers the formation of foam cells, damages endothelial cells, and regulates 
many inflammatory mediators to control leukocyte recruitment and retention. In brief, 
LDL and OxLDL in the bloodstream enter the intima, where both are further modified 
by the enzymes and oxygen radicals therein. This modification leads to the secretion 
of pro-inflammatory mediators, to the initiation and maintenance of inflammation, 
and to the recruitment and differentiation of macrophages in the intima (Rader & 
Daugherty, 2008). Macrophages recognise and clear OxLDL, thereby forming the 
foam cells that result in the plaque that eventually leads to clinical events. 
 
Aggregation and oxidation of entrapped LDL in the arterial wall is the key event 
during the formation of foam cells. Scavengers receptors (SRAI/II, CD36, SR-BI, and 
LOX-1) stimulate the phagocytosis of OxLDL, which results in a massive 
accumulation of cholesterol and hence the generation of foam cells. OxLDL enhances 
the adhesion to and hence the infiltration of macrophages into the arterial wall. 
OxLDL also enhances the migration and proliferation of smooth muscle cells 
(Mertens, et al., 2001). 
 
OxLDL damages endothelial cells and inhibits the differentiation of endothelial 
progenitor cells (Ma, et al., 2006). This results in endothelial activation and the 
expression of adhesion molecules mentioned above. 
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OxLDL stimulates the expression of many inflammation-related genes, including 
platelet-activating factor, tissue factor, monocyte colony-stimulating factor (M-CSF), 
monocyte chemoattractant protein 1 (MCP-1), vascular cell-adhesion molecule 
(VCAM), CD40/CD40L, collagen synthesis of smooth muscle cells, intracellular 
calcium, matrix metalloproteinases, IL 1, IL 6, IL 8, nuclear factor-κB, CRP, and 
TNF-α (Steinberg, 2002) (Verhoye, et al., 2009). 
 
The removal of OxLDL from circulation inhibits atherosclerotic progression. Ishigaki 
et al. over-expressed LOX1, an OxLDL receptor, in ApoE(-/-) mice and reported a 
great reduction of atherosclerosis lesion and stabilisation of plaques (Ishigaki, et al., 
2008). 
 
The exact cellular mechanisms of these atherogenic effects of OxLDL are not yet 
clear. Tabas proposed that free cholesterol derived from OxLDL might induce 
programmed cell death (apoptosis) of macrophages (Tabas, 2004). Free cholesterol 
accumulates steadily in the endoplasmic reticulum (ER) membrane, which is normally 
cholesterol-poor. This accumulation induces ER stress signals in the transduction 
pathway, known as the unfolded protein response. A part of this response prompts an 
apoptotic response in the macrophages and compromises the clearance of debris, 
which may accelerate the progression of atherosclerotic lesions. 
 
2.3.4 Clinical observations relating OxLDL to atherosclerosis  
Immunoassays have been developed that can identify OxLDL in circulation or in 
tissues. The main pitfall of assays using monoclonal antibodies is that a given 
antibody recognises only one of the numerous epitopes on OxLDL, and may therefore 
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capture only a fraction of the total OxLDL in serum. Although measuring such a 
complex particle by a single episode is not perfect, most clinical studies have used 
one of the following monoclonal antibodies: 4E6 which reacts with apoB peptides 
(Holvoet, et al., 1998), DLH3 which reacts with phosphatidylcholine (Itabe, et al., 
1994), or EO6 which reacts with phosphorylcholine (Palinski, et al., 1996). 4E6 was 
commercialised by Mercodia and has been widely used. There exist many other 
antibodies that have been raised by a range of methods. Itabe proposed a classification 
for these antibodies according to their reactivity with LDL oxidative modification and 
apoB peptide fragments (Itabe, 2009). Obviously measurements obtained by different 
antibodies cannot be compared directly (Fraley & Tsimikas, 2006). 
 
The level of circulating OxLDL correlates with many diseases and has been suggested 
as an indicator of atherosclerosis (Fraley, et al., 2006). For example, circulating 
OxLDL is found to be associated with subclinical atherosclerosis (Hulthe & 
Fagerberg, 2002). Table 2-1 summarises the correlation between OxLDL and 
atherosclerosis. That these non-standardised assays of OxLDL have wide 
heterogeneity raises an important and critical issue: the various published linkages 
between OxLDL and CAD are not comparable (Verhoye, et al., 2009).  
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Table 2-1 Some of the studies that show OxLDL as a biomarker of atherosclerosis. 
Study (author and reference) Subjects Method Study design or endpoints Result 
Ehara (Ehara, et al., 2001) 45 AMI, 45 UAP, 45 SAP, 
and 46 control 
Sandwich ELISA (DLH3) Cross-sectional OxLDL: AMI>UAP>SAP 
Holvoet (Holvoet, et al., 2001) 178 CAD, 126 control 4E6 Cross-sectional OxLDL: CAD>control  
Wallenfeldt (Wallenfeldt, et al., 2004) 326 healthy 58 years old men 4E6 Kit (Mercodia AB) 3-year follow-up, carotid IMT ↑OxLDL related to progression 
Faviou (Faviou, et al., 2005) 41 UAP, 62 SAP, 170 control 4E6 Kit (Mercodia AB) Cross-sectional OxLDL: USA> SAP or control 
Ndrepepa (Ndrepepa, et al., 2005) 687 CAD with statin or 
placebo 
4E6 Kit (Mercodia AB) Cross-sectional ↓OxLDL in statin group 
Tsimikas, (Tsimikas, et al., 2006) 826 subjects in Bruneck study Ox-PL/apoB (by E06)  5-year follow-up, carotid and 
femoral IMT 
↑ Ox-PL/apoB related to 
progression 
Kiechl (Kiechl, et al., 2007) 765 subjects in Bruneck study Ox-PL/apoB (by E06)  10-year follow-up, CV death, 
MI, stroke 
↑ Ox-PL/apoB related to event 
AMI: acute myocardial infarction, CAD: cardiovascular disease, IMT: intima-media thickness, NIDDM: non-insulin dependent diabetes 
mellitus, SAP: stable angina pectoris, UAP: unstable angina pectoris 
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2.4 Anti-OxLDL antibodies in atherosclerosis  
Researchers have proposed many molecules such as LDL-cholesterol, CRP, 
lipoprotein-associated phospholipase A2 (Lp-PLA2), myeloperoxidase (MPO), 
oxidized LDL, lipoprotein (a) and isoprostanes as potential biomarkers of 
atherosclerosis (Tsimikas, 2006a). Most of those molecules more or less reflect 
oxidizing stress. Antibodies against OxLDL have also attracted attention in the field 
of biomarker research. 
 
The characteristics and correlation of OxLDL antibodies in patients with 
atherosclerosis have been investigated by many researchers for more than two 
decades. Unfortunately, numerous clinical studies have shown widely inconsistent 
and sometimes contradictory conclusions. Many studies have reported negative 
correlation between anti-OxLDL antibodies and atherosclerosis (Table 2-2) (page 31), 
while many others have reported positive (Table 2-3, page 34) or neutral associations. 
(Table 2-4, page 38) (Hulthe, 2004; Miller, et al., 2009; Shoenfeld, et al., 2004). 
 
The foregoing inconsistency between studies suggests that it could be very difficult to 
use presently available techniques to examine the exact roles of anti-OxLDL 
antibodies. A more accurate and standardized method that allows comparisons 
between studies is needed.  
 31 
Table 2-2 These studies show that OxLDL antibodies correlate NEGATIVELY with atherosclerosis 
Study (author and reference) Subjects Antibody Study design or 
endpoints 
Result 
Schumacher (Schumacher, et al., 1995) 15 AMI Cu-OxLDL Cross-sectional ↓ IgG Cu-OxLDL during the acute phase  
Festa (Festa, et al., 1998) 94 IDDM, 27 control Cu-OxLDL Cross-section, 
HbA1c 
Inverse correlation between Ab-Cu-OxLDL 
and HbA1c, but ↑ Ab-Cu-OxLDL in IDDM 
Iughetti (Iughetti, et al., 1999) 18 children and 35 adults Cu-OxLDL, MDA-LDL  Case-control ↑ IgG Cu-OxLDL, MDA-LDL in children 
Lopes-Virella (M. F. Lopes-Virella, et 
al., 1999) 
49 IDDM, 49 controls Cu-OxLDL  Case control, 8-
year follow-up 
IgG Cu-OxLDL in IDDM with CAD < IDDM 
without CAD 
Lehtimäki (Lehtimäki, et al., 1999) 58 CAD, 34 control Cu-OxLDL IgG Case-control ↑ IgG Cu-OxLDL in CAD 
Wu (Wu, et al., 1999) 73 men with borderline HTN 
and 75 controls 
Cu-OxLDL, MDA-LDL Case-control ↓IgG & IgM anti-Cu-OxLDL in borderline HT 
Fukumoto (Fukumoto, et al., 2000) 514 healthy subjects OxLDL (Biomedica kit) Cross-sectional,  
Carotid IMT 
Inverse correlation between Ab-OxLDL and 
IMT 
Shoji (Shoji, et al., 2000) 130 healthy OxLDL (Biomedica kit) Cross-sectional  Inverse correlation between Ab-OxLDL and 
LDL  
Dotevall (Dotevall, et al., 2001) 46 AMI, 70 controls,  MDA-LDL  Case-control ↓IgM anti-MDA-LDL in cases 
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Hulthe (Hulthe, Wiklund, et al., 2001) 102 hypercholesterolemia, 
102 controls 
Cu-OxLDL, MDA-LDL  Carotid IMT ↓ IgG anti-Cu-OxLDL in cases,  
IgM anti-Cu-OxLDL related inversely to IMT  
Hulthe (Hulthe, Bokemark, et al., 2001) 388 health 58-year old men Cu-OxLDL, MDA-LDL  Femoral IMT.  ↓ IgM anti-Cu-OxLDL related to progression 
Shoji (Shoji, et al., 2002) 249 ESRD OxLDL (Biomedica kit) CV mortality ↓IgG anti-Cu-OxLDL related to higher CV 
mortality  
Zezina (Zezina, et al., 2002) 92 kidney graft recipients Cu-OxLDL Cross-sectional ↓Ab Cu-OxLDL associated with graft loss 
Karvonen (Karvonen, et al., 2003) 1022 middle-aged men and 
women cohort 
Cu-OxLDL, MDA-LDL Carotid IMT ↓IgM anti-Cu-OxLDL related to progression;  
MDA-LDL IgM related inversely to IMT 
Shoji (Shoji, et al., 2003) 103 ESRD OxLDL (Biomedica kit) Carotid IMT ↓↓ IgG anti-Cu-OxLDL related to 
atherosclerosis 
Fernandes (Fernandes, et al., 2004) 15 unstable angina, 15 stable 
angina 
Cu-OxLDL Cross-sectional ↓ IgG anti-OxLDL in unstable angina 
Su (Su, et al., 2006) 226 essential HTN Cu-OxLDL IgM, PC IgM Carotid IMT ↑ IgM anti-Cu-OxLDL or anti-PC predict 
lower IMT change ; ↑ Ab-OxLDL in Women  
Sjögren (Sjogren, et al., 2008) 377 AMI, 387 controls Native apoB-100 peptide 
(p210) 
Cross-sectional ↓ IgG anti-p210 (native) in cases, 
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AMI: acute myocardial infarction, CAD: coronary artery disease, DM: diabetes mellitus, ESRD: end-stage renal disease, HTN: hypertension, 
IDDM: insulin dependent diabetes mellitus, IMT: intima-media thickness, 
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Table 2-3: These studies show that OxLDL antibodies correlate POSTIVELY with atherosclerosis 
Study (author and reference) Subjects Antibody Study design or 
endpoints 
Result 
Salonen (Salonen, et al., 1992) 30 patients with carotid 
atherosclerosis & 30 controls 
MDA-LDL vs N-LDL 
 
2-year follow-up, Carotid 
IMT.  
↑ Ab-MDA-LDL related to progression 
Maggi (Maggi, et al., 1994) 94 carotid disease and 42 controls IgG, IgM-CuLDL, IgG, 
IgM-MDA-LDL 
Cross-sectional All 4 antibodies are ↑ in cases 
Puurunen (Puurunen, et al., 
1994) 
135 patients with CAD, 135 
controls 
MDA-LDL Cross-sectional ↑ IgG anti-MDA-LDL in cases 
Bergmark (Bergmark, et al., 
1995) 
62 peripheral vascular disease, 62 
controls 
Cu-OxLDL Cross-sectional ↑IgG anti-Cu-OxLDL in case 
Bui (Bui, et al., 1996) 25 patients with CAD, 28 controls Cu-OxLDL Cross-sectional ↑IgG anti-Cu-OxLDL in case 
Heitzer (Heitzer, et al., 1996) 30 hypercholesterolemia,15 
smokers, 10 controls 
Cu-OxLDL Forearm blood flow as 
endothelial function 
↑IgG anti-Cu-OxLDL related to impaired 
function 
Raitakari (Raitakari, et al., 
1997) 
30 healthy men Cu-OxLDL Cross-sectional, coronary 
flow evaluated by PET 
IgG anti-Cu-OxLDL inversely associated 
with flow reserve 
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Wu (Wu, et al., 1997) 119 patients with MI, 138 controls Cu-OxLDL Cross-sectional ↑IgG anti-Cu-OxLDL in case 
George (George, et al., 1999) 72 patients underwent PTCA Cu-OxLDL vs N-LDL 
 
restenosis in PTCA ↑ Ab-OxLDL 
Dotevall (Dotevall, et al., 2001) 46 patients with MI, 70 controls,  MDA-LDL  Case-control ↑IgG anti-Cu-OxLDL in cases 
Fagerberg (Fagerberg, et al., 
2001) 
391 health 58-year old men Cu-OxLDL, MDA-LDL  Cross-sectional ↑ IgG anti-Cu-OxLDL and IgG anti-MDA-
LDL related to metabolic syndrome 
Hulthe (Hulthe, Bokemark, et 
al., 2001) 
388 health 58-year old men Cu-OxLDL, MDA-LDL  Carotid IMT. 
 
↑IgG anti-Cu-OxLDL related to 
progression 
Monaco (Monaco, et al., 2001) 58 UAP, 28 stable angina, 20 
peripheral artery disease 
Cu-OxLDL Case-control ↑IgG anti-Cu-OxLDL in peripheral disease 
Sherer (Sherer, et al., 2001) 126 CAD, 20 controls,  Cu-OxLDL Cross-sectional ↑IgG anti-Cu-OxLDL in CAD 
Swets (Swets, et al., 2001) 24 systemic vasculitis, 44 controls MDA-LDL Cross-sectional ↑IgG anti-MDA-LDL in case 
Fnag (Fang, et al., 2002) 36 cardiac transplant MDA-LDL Cross-sectional, coronary 
endothelial function 
↑IgG anti-MDA-LDL associated with 
dysfunction  
Inoue (Inoue, et al., 2002) 39 patients with AMI, 25 controls MDA-LDL Cross-sectional ↑IgG anti-MDA-LDL in case 
Meraviglia (Meraviglia, et al., 
2002) 
52 carotid endarterectomy Cu-OxLDL, MDA-LDL  Carotid IMT ↑IgG & IgM anti-Cu-OxLDL related with 
progression 
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Orem (Orem, et al., 2002) 44 patients with dyslipidemia Cu-OxLDL IgG Change after statin ↓ IgG anti-Cu-OxLDL after treatment 
Fredrikson (Fredrikson, et al., 
2003) 
78 patients with CAD, 149 controls MDA-ApoB peptides (20 
Amino acids each) 
Cross-sectional, carotid 
IMT 
↑ IgM associated with carotid IMT in 
groups < 60 years old 
Doo (Doo, et al., 2004) 60 patients with UAP OxLDL (Biomedica kit) Cross-sectional ↑Ab anti-OxLDL predicted lower event 
free survival 
Bilgen (Bilgen, et al., 2005) 136 patients with CAD, 31 controls OxLDL (Biomedica kit) Cross-sectional Ab-OxLDL: CAD > control 
Faviou (Faviou, et al., 2005) 41 UAP, 62 SAP, 170 controls OxLDL (Biomedica kit) Case-control Ab-OxLDL: UAP > SAP > control 
Wu (Wu, et al., 2005) 74 HTN, 68 MI, 125 health controls Ox-PAPC 
 
Cross-sectional ↑ IgG and IgM ox-PAPC in cases 
Rodenburg (Rodenburg, et al., 
2006) 
178 children with FH and their 
unaffected siblings 
MDA-LDL Cross-sectional ↑IgM anti-MDA-LDL in case 
George (George, et al., 2006) 102 heart failure Cu-OxLDL NYHA score ↑ IgG anti-Cu-OxLDL related to severity 
of heart failure 
Karolkiewicz (Karolkiewicz, et 
al., 2006) 
26 men > 74 years old, 83 men < 74 
years old 
OxLDL (Biomedica kit) Cross-sectional ↑ Ab-OxLDL in older men 
Soltesz (Soltesz, et al., 2007) 34 ACS, 62 stable CAD, 50 
controls 
OxLDL (IMMCO kit) Cross-sectional,  ↑IgG anti-OxLDL in case 
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Fredrikson, (Fredrikson, 
Hedblad, et al., 2007) 
751 subjects in BCAPS trial MDA apoB-100 peptide 
(p210) 
Cross-sectional, carotid 
IMT 
↑ IgG anti-MDA-p210 related to 
progression 
Santos (Santos, et al., 2009) 116 ACS with metabolic syndrome, 
96 controls with HTN 
IgG Cu-OxLDL Cross-sectional ↑IgG anti-Cu-OxLDL in ACS 
Greco (Greco, et al., 2009) 344 patients with ACS Cu-OxLDL/β2GPI Cross-sectional, coronary 
angiography 
↑ IgG anti-Cu-OxLDL/β2GPI related to 
CAD severity 
Charach (Charach, et al., 2009) 284 patients with CHF Cu-OxLDL IgG Retrospective, follow up 
3.7 years, Hospitalization 
or mortality 
↑ IgG anti-Cu-OxLDL predicted morbidity 
and mortality 
AMI: acute myocardial infarction, CAD: coronary artery disease, HTN: hypertension, IDDM: insulin dependent diabetes mellitus, IMT: intima-
media thickness, FH: familial hypercholesterolemia, PAPC: 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine, PL: phospholipid, PTCA: 
percutaneous transluminal coronary angioplasty, SAP: stable angina pectoris, UAP: unstable angina pectoris,  
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Table 2-4: These studies show that OxLDL antibodies do NOT correlate with the atherosclerosis 
Study (author and reference) Subjects Antibody Study design or 
endpoints 
Result 
Virella (G Virella, et al., 1993) 33 CAD, 64 controls Cu-OxLDL Case control No difference 
Boullier (Boullier, et al., 1995) 70 CAD, 70 controls MDA-LDL IgG Cross-sectional No difference 
Uusitupa (Uusitupa, et al., 1996) 91 NIDDM, 82 controls Cu-OxLDL, Case-control No difference 
van de Vijver (van de Vijver, et 
al., 1996) 
47 severe CAD, 47 mild  
CAD, 49 health controls 
MDA-LDL Coronary angiography No difference 
Iribarren (Iribarren, et al., 1997) 231 carotid atherosclerosis and 231 controls MDA-LDL IgG Cross-sectional, carotid 
IMT 
No difference between case and 
control 
Hulthe (Hulthe, et al., 1998) 51 patients with FH and 45 controls Cu-OxLDL vs. MDA-
LDL vs. N-LDL 
Carotid IMT. 
 
No difference  
Ahmed (Ahmed, et al., 1999) 149 stroke and 233 controls Cu-OxLDL, MDA-
LDL 
Cross-sectional, Stroke 
vs. control 
No difference 
Mironova (Mironova, et al., 
2000)  
20 NIDDM, 14 CAD without DM, 34 
controls 
Cu-OxLDL Cross-sectional No difference 
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Paiker  (Paiker, et al., 2000) 50 homozygous Familial 
Hypercholesterolemia with or without CAD, 
10 health controls 
Cu-OxLDL, Carotid IMT, 
 
No difference 
Tsimikas (Tsimikas, et al., 2004) 
 
2341 ACS with statin treatment in MIRACL 
trial 
MDA-LDL, 16 weeks follow-up No difference between statin and 
placebo 
Erkkilä (Erkkilä, et al., 2005) 284 male and 129 female patients in 
EUROASPIRE study 
Cu-OxLDL 5-year follow-up, CAD 
death, AMI 
Not predictor for events 
Mayr (Mayr, et al., 2006) 826 subjects in Bruneck study Cu-OxLDL, MDA-
LDL, IC/apoB,  
5-year follow-up, carotid 
IMT 
No correlation (in multivariate 
analysis) 
Wilson (Wilson, et al., 2006) 1192 men and 1427 women in Framingham 
Offspring Study 
MDA-LDL IgG and 
IgM 
8-year follow-up Not related to CAD event 
incidence, (but strongly positively 
related to age) 
Tsimikas (Tsimikas, et al., 2007) 504 CAD underwent angiography Cu-OxLDL, MDA-
LDL,  
4-year follow-up,  No correlation 
Choi (Choi, et al., 2008) 214 CAD with statin treatment in 
REVERSAL study 
MDA-LDL, IC/apoB, 
MDA/apoB, 
Head to head, coronary 
angiography parameters 
and atheroma volume 
No correlation 
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Fraley (Fraley, et al., 2009) 2342 ACS with statin treatment in MIRACL 
trial 
MDA-LDL, CRP, SAA, tPA, IL-6, 
ICAM, VCAM, P-
selectin, E-selectin,  
No correlation 
ACS: acute coronary syndrome, CAD: coronary artery disease, CRP: C-reactive protein; ICAM: intercellular adhesion molecule, NIDDM: non-
insulin dependent diabetes mellitus, SAA: serum amyloid A; tPA: tissue plasminogen activator; IL-6: interleukin-6; VCAM: vascular cell 
adhesion molecule. 
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2.4.1 Explanations of complex observations  
Significant uncertainty still surrounds the clinical significance of how antibodies 
affect modified LDL in atherosclerosis because existing epidemiological and clinical 
investigations that correlate titre of modified LDL in circulation and various end 
points of CAD reveal conflicting data and conclusions (Shoenfeld, et al., 2004). 
Researchers have attributed this discrepancy to numerous factors: the biological 
variability in immune responses, the interaction between antigen and immune 
complex, isotypes, the variation of antigen per se, varying affinity and avidity of 
antibodies, different endpoints and finally a lack of comparability between different 
assays used (G. Virella & Lopes-Virella, 2003) (Hulthe, 2004) (Miller, et al., 2009). 
For example, although using the same method of oxidation, the LDL purified from 
different individuals may have different characteristics that may significantly affect 
the resulting OxLDL antibodies (T. Wang, et al., 2002). 
 
The complexity of OxLDL as an antigen, the variability of LDL which is determined 
by the source (T. Wang, et al., 2002), and the oxidation of LDL ex vivo all contribute 
to the strikingly large and characteristically distinctive array of antigens that are used 
in OxLDL antibodies assays which researchers use in their studies. Furthermore, 
individuals may have distinct amounts of antibodies to different fractions in a single 
preparation of OxLDL (Ketelhuth, et al., 2008). For example, patients with unstable 
angina had lower levels of IgG anti high molecular weight fractions of OxLDL but 
higher levels of IgG anti low molecular weight of fractions compared to the control 
group (Ketelhuth, et al., 2008). 
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2.5 Representative material of OxLDL 
One of the most straight forward approaches that one can use to study such a huge 
complex antigen as OxLDL is cut it into smaller pieces and then screen the 
associations between these small antigen pieces and the whole antigen. Nilsson’s 
group used apoB peptides (length of 20 amino acids, with or without modification) as 
surrogate material in the measurement of OxLDL-related antibodies. They reported 
several significant correlations between anti-apoB peptide antibodies and 
atherosclerosis (Sjogren, et al., 2008) (Fredrikson, Schiopu, et al., 2007) (Fredrikson, 
et al., 2003). However, there are two obvious possible limitations in this set of 
Nilsson’s experiments: 1) short linear peptides could not represent a possible 
conformational epitope, 2) these apoB-based experiments did not take into account 
the possible effects of the lipid components of OxLDL. 
 
Another commonly used epitope of OxLDL is PC, which is also expressed on 
bacterial cell wall and apoptotic cells (Shaw, et al., 2003). Antibody against PC 
blocks intake of OxLDL by macrophages and correlates negatively with 
atherosclerosis (Binder & Silverman, 2005; de Faire & Frostegård, 2009; Shaw, et al., 
2000). Furthermore, immunization with pneumococcal vaccine (Binder, et al., 2003) 
or even PC attached to a non-specific protein carrier (keyhole limpet haemocyanin) 
(Caligiuri, et al., 2007) can reduce or slow the development of atherosclerosis (de 
Faire, et al., 2009). PC, however, is part of phospholipid, which means that it does not 
represent the protein part of LDL.  
 
There is an interesting aspect of the antigenicity of PC, stemming from anti-PC 
monoclonal antibodies bearing the T15 idiotype, that is relevant to my results to be 
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described below. T15 is the most commonly used monoclonal antibody specific to 
PC. The antigen binding regions, which comprise variable regions of heavy chain 
(VH) and light chain (VL), determine the specificity of a given immunoglobulin. 
Among the variable regions, three more specifically variable loops, or 
complementarity determining regions (CDRs), provide the major antigen binding site. 
A peptide sequence of the heavy chain of these antibodies comprising a part of the 
CDR2(VH) and flanking framework (FR) 3 has been reported to be an antigenic 
mimic of PC and also to mediate self-binding of T15 antibodies (Kang & Kohler, 
1986)  (Kang, et al., 1988) (Harris, et al., 2000). Figure 2-1 shows a model that may 
explain this self-binding capability (Zhao, et al., 2005). 
 
Figure 2-1 Schematic interaction pattern of T15 self-binding 
Two hydropathically complementary sequence of T15 antibody VH chain are lined up 
(Zhao, et al., 2005). Arrows indicate complementary amino acid pairs. FR3: 
framework region 3. 
 
In view of the above-mentioned limitations in studying Ox LDL as an antigen, we 
hypothesize that anti-idiotypic (anti-id) antibodies might be more mimetic. The theory 
of anti-id antibodies was first suggested by Niels Kaj Jerne in the early 1970’s 
(Hantusch, et al., 2006). He proposed that the immune system might also recognize its 
own constituent components such as an antibody itself. When the immune system 
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responds to a given antigen by producing antibodies (Ab1), the system also produces 
corresponding anti-id antibodies (Ab2) against Ab1. Some of these anti-id antibodies 
were predicted to serve as the “internal images” of the original antigen. Therefore 
Ab2 could have similar shapes and immunogenic functions as the original antigen 
(Figure 2-2) (Greenspan & Bona, 1993). Hoffmann coined a shorthand to denote this 
network relationship between the original antigen and its “internal image”: “Anti-anti-
X can resemble X.” (Hoffmann, 2008) 
 
For a long time researchers have studied the functional epitopes of antigens 
recognised by Ab1 indirectly by analysing their “internal image” in Ab2. Anti-ids 
have been used mainly in cancer research as potential therapies or vaccinations (de 
Cerio, et al., 2007) (Coelho, et al., 2004). Anti-ids can also serve as substitutes for 
antigens when the original antigens are too difficult to obtain or are highly toxic 
(Behn, 2007). 
 
When it come to mimicking huge complex antigens, anti-ids have some theoretical 
advantages over short peptides: anti-ids provide potential conformational recognition 
sites while linear apoB peptides do not, and anti-ids might have stronger affinity due 
to their larger size than short peptides. A schematic analogy of immune network 
related to OxLDL is shown in Figure 2-3. 
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Figure 2-2 Antigen, antibody, and anti-idiotypic antibody 
The schematic graph demonstrates the network of antigen (Ag), antibody (Ab1), and 
anti-idiotypic antibody with internal image (Ab2). Ab2 might mimic the original 
antigen in shape and in function. 
 
 
Figure 2-3 Schematic of an idiotype network related to oxidized LDL. 
OxLDL, the antigen, is recognized by the monoclonal antibody. This antibody is then 
recognized by anti-idiotypic antibody (anti-id). 
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CHAPTER 3 Results I: the production and characteristics 
of monoclonal anti-OxLDL antibodies 
3.1 Introduction 
To investigate the role of anti-OxLDL antibodies in atherosclerosis, many monoclonal 
antibodies have been studied and reported using mouse models. Witztum’s group 
cloned several monoclonal antibodies from apoE(-/-) mice (Palinski, et al., 1996). The 
most commonly used antibody from this work has been the IgM clone EO6, which 
was shown to react with the phosphocholine head group of phospholipids in various 
antigens such as OxLDL (Horkko, et al., 1999) and apoptotic cells (M. K. Chang, et 
al., 1999). EO6 has been one of the major autoantibodies against OxLDL used in 
atherosclerosis studies for more than a decade. Other commonly used antibodies in 
atherosclerosis research are against either phosphatidylcholine (DLH3) (Itabe, et al., 
1994) or apoB peptides (4E6) (Holvoet, et al., 1995). 
 
The first step of my project was to obtain a novel monoclonal anti-OxLDL 
autoantibody to serve as Ab1 for further in depth analysis in the immune network 
(Figure 2-2). In this chapter I report how I cloned several monoclonal anti-OxLDL 
antibodies from the splenocytes of a non-immunized LDLr(-/-) mouse. The methods 
and materials for ELISA detection of anti-OxLDL antibodies, fusion of hybridomas, 
screening and purification of monoclonal anti-OxLDL antibodies, and sequencing of 
immunoglobulin genes are described in section 3.2. The detailed results of screening, 
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specificity, and sequence of variable regions of antibodies that I obtained antibodies 
follow in section 3.3. 
3.2 Methods and Materials 
3.2.1 The modification of LDL 
Human LDL (Sigma, Cat# L7914) was dialyzed against PBS overnight at 4°C to 
remove EDTA. Dialyzed LDL at 100 µg per ml was then incubated with freshly 
prepared CuSO4 (10 µM) at 37°C for 4 or 24 hours to give a moderately or an 
extensively oxidized product, respectively. The oxidisation reaction was stopped by 
adding an excess amount of chelating resin Chelex 100 (Sigma C-7901). The extent 
of LDL modification was estimated by the relative electrophoretic mobility of the 
LDL particles using pre-cast 0.5% agarose gels (LIPO lipoprotein electrophoresis kit, 
Beckman, Cat# 655910, CA). LDL oxidised for 24 hours by CuSO4 was used as the 
standard antigen in ELISAs throughout this project 
 
MDA modified LDL was prepared according to the protocols described by Palinski 
et, al (Palinski, et al., 1990). MDA was synthesised by the acid hydrolysis of 
malondialdehyde bis dimethylacetal (Sigma, T9889). Dialysed human LDL was 
incubated for 3 hrs at 37°C with 0.5M MDA at a ratio of 100ul MDA/mg LDL. The 
extent of modification was estimated with a carbonyl assay (Uchida, et al., 1998). 
Briefly, 0.1 mg of modified LDL was put into 500µl of 4mg/ml BSA. To this, 700µl 
of 0.1% (wt/vol) 2,4-dinitrophenylhydrazine (DNP) in 2M HCl was added and then 
incubated for 1 hour at RT. Again, to this 500µl of 30% trichloroacetic acid was 
added. The mixture was then centrifuged for 5 min; 14000 rpm at 4ºC, and then it was 
left on ice for 30 minutes. The precipitate was then washed three times with 
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ethanol/ethyl acetate (1:1, vol/vol). The pellet was finally dissolved in 1ml of 8M 
guanidine hydrochloride, 13mM EDTA and 133mM Tris pH 7.4 and the OD read at 
365nm. The results were expressed as the number of moles of DNP/mg of protein 
(mol/mg) using an extinction coefficient of 21mM-1/cm-1.  
3.2.2 ELISA  
Antibodies used in this project are listed in Table 3-1. Nunc Maxisorb 96-well plates 
(NUNC, Cat# 475094, Leicestershire) were coated with 50 µl/well (10µg/ml) of 
oxidized LDL (OxLDL) or native LDL, or 50 µl/well (1µg/ml) of PC-BSA in PBS 
containing 0.27 mM EDTA at 4°C overnight. Non-adherent material was washed out, 
and then the plates were blocked with 2% BSA/PBS for 1 hour at RT. Appropriately 
diluted serum or culture supernatant was added and incubated for 1 hour at RT. After 
that, plates were washed, and bound antibodies were incubated with secondary 
antibody at appropriate dilution. After further washing, antibody binding was detected 
with 3,3,5,5-tetramethylbenzidine (TMB) (Sigma, Cat# T0440), and the reaction was 
stopped with 0.5M H2SO4 for 20 minutes. The optical density was then measured with 
a Synergy HT microplate reader (Biotek, USA) at wavelength 450nm. 
 
Origin Specificity Conjugate Supplier Category number Dilution 
Goat Human IgG Biotin Southern 2043-08 1/2000 
Mouse Human IgM Biotin Southern 9020-08 1/2000 
Goat Human IgA Biotin Southern 2050-08 1/1000 
Goat Mouse IgG Biotin Southern 1030-08 1/2000 
Goat Mouse IgM Biotin Southern 1020-08 1/2000 
Goat Mouse IgA HRP Caltag M31007 1/2000 
Table 3-1 Antibodies used in ELISAs.
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3.2.3 Fusion and screening of hybridomas 
The mouse used for generating hybridomas was a one-year-old female LDLr-/- mouse 
that had been fed high fat diet from the age of 6 weeks old. The mouse was not 
exogenously immunized prior to the experiment. Based on experience in our 
laboratory, the mouse was likely to have a high level of cholesterol (25-30 mmol/l). 
The details of how mice were maintained, and the composition of the diet are 
described in section 5.2.1.1 (page 94). The splenocytes from the mouse was fused 
with the Sp2/0-Ag14 myeloma cell line (ATCC-LCG, Cat# CRL-1581, Middlesex).  
Sp2/0 myeloma cells were maintained in Dulbecco's Modified Eagle Medium 
(DMEM) (Invitrogen, cat # 31053-028), supplemented with heat inactivated FBS 
(10%, v/v), 100 IU/mL penicillin/streptomycin and 2mM L-glutamine, and grown at a 
cell density of between 1 and 5 x 105 cells/ml before fusion.  Twenty million washed 
Sp2/0 cells were fused with 108 washed splenocytes by treating the cell mixture with 
PEG (50%, v/v) for 4 minutes. PEG was then removed by centrifuging at 400 x g for 
7 minutes and the cells were then resuspended in DMEM with FBS for 24 hours at 
37°C in 5% CO2 atmosphere. 
 
Following the fusion, hybridomas were cultured using a semi-solid medium-based 
method (ClonaCell®-HY, cat# 28411, Stemcell Technologies) in selection and 
cloning medium (DMEM, 10% methylcellulose v/v) supplemented with 2% v/v HAT 
(hypoxanthine, aminopterin, and thymidine; final concentration: hypoxanthine 1x10-4 
M, aminopterin 4 x 10-7 M, and thymidine 1.6 x 10-5 M), 100  IU/mL 
penicillin/streptomycin and 2mM L-glutamine at 37°C for 14 days without any 
disturbance.  
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Isolated colonies were pipetted into individual wells of a 96-well tissue culture plate 
containing 200 µl of growth medium (DMEM, 2% HT v/v, 100 IU/mL 
penicillin/streptomycin and 2mM L-glutamine) per well.  After 4 days of expansion, 
hybridoma supernatants were screened by ELISA (see section 3.2.2) for the presence 
of antibodies that bound with OxLDL or native LDL. The specificities of hybridoma 
supernatants were determined by solid phase binding and competition ELISAs.  
Hybridomas with differential reactivity to native LDL and OxLDL were chosen for 
further characterization and two rounds of subcloning. Clones secreting candidate 
antibodies for further study were expanded in 25 and 75 cm2 flasks (Nunc, Denmark), 
harvested, and cryopreserved in 50% FCS and 15% dimethyl sulfoxide (DMSO; 
Sigma) at -80°C. The isotypes of candidate hybridomas were determined using a 
mouse monoclonal antibody isotyping kit (IsoStrip, Roche Applied Science, Cat# 
11493027001, Burgess Hill). 
 
3.2.4 Production and purification of monoclonal antibodies 
The selected hybridomas were expanded in two-compartment bioreactors (IBS-
INTEGRA Biosciences, Cat# CL1000, Chur, Switzerland) using Dulbecco's modified 
Eagle medium (Gibco, Cat# 12491) supplemented with 10% immunoglobulin G 
depleted fetal bovine serum (Gibco, Cat# 16250), 2 mM glutamine, 50 u/mL 
penicillin, 50 µg/mL streptomycin. The harvesting cycles lasted 8 to 10 days. The 
antibodies in the hybridoma culture supernatants were purified by protein-G affinity 
chromatography (Sigma, Cat P3296). The captured monoclonal antibody was eluted 
with 0.1M glycine (pH=2.7) and neutralised with 1M Tris buffer (pH=8.8).  
Following extensive dialysis against PBS, the concentration of antibodies was 
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estimated by spectrometry at a wavelength of 280nm. The final product was preserved 
in a 0.05% sodium azide at -80°C until use in assays. 
3.2.5 Sequencing of variable regions of hybridoma clones 
Total RNA was extracted from 107 hybridoma cells using a RNAeasy Mini Kit 
(Qiagen, Cat# 74104, West Sussex). cDNA was synthesized with a First Strand 
cDNA synthesis kit (Invitrogen, cat# 18080051) and an oligo (dT) primer. Mouse IgG 
cDNA complete variable regions were amplified by PCR using a series of degenerate 
oligonucleotide primers, which had been prepared by MWG-Eurofins. 
 
The sense primers based on framework 1 (Nicholls, et al., 1993) were used in 
combination with a universal antisense constant region oligonucleotide (Z. Wang, et 
al., 2000) to amplify the whole variable region and the start of the CH1 region.  The 
primers are listed in Table 3-2 and Figure 3-1. The expected sizes of the amplified 
products of heavy and light chains are about 400 and 380 bp, respectively. 
 
Each PCR reaction contained 0.4 µg of cDNA template and 10 pmol of 
oligonucleotide primer. Taq polymerase, dNTP, and reaction buffer were 
supplemented into reaction. The thermal cycle included denaturation at 94°C for 30 
seconds, annealing at 55°C for 30 seconds, and elongation at 72°C for 90 seconds, 
and the process was repeated for a total of 30 cycles.  
 
The PCR products of hybridoma variable regions were separated on 1% agarose gel 
electrophoresis and then purified for sequencing. The nucleotide sequences were 
determined by an ABI 3730 automated DNA analyzer. The VH-(D)-JH and the Vκ-Jκ 
sequences were analyzed by National Center for Biotechnology Information (NCBI) 
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IgBlast database (http://www.ncbi.nlm.nih.gov/igblast/) and the International 
MunoGeneTics information system® (IMGT) (http://www.imgt.orgIMGT) (Lefranc, 
et al., 2009). 
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Table 3-2 Primers used for amplifying variable regions 
For VH Primers  
Forward VH-II 5-CAG GTC CAR CTG CAG CAG YCT-3 
Reverse IgG3 5-AGG GAC CAA GGG ATA GAC AGATGG-3 
 Rev-g 5-CC KYG GTS YTG CTG GCY GGG TG-3 
For VL   
Forward VL-I/III 5-GAC ATT GTG ATG ACY CAR TCT-3 
Reverse k-rev2 5-CTG CTC ACT GGA TGG TGG GAA-3 
 k-rev 5-TTA ACA CTC ATT CCT GTT GAA GC-3 
 
Figure 3-1 Positions of primers used for sequencing variable regions 
This schema shows the positions of the primers used for amplifying and sequencing 
the immunoglobulin variable regions of hybridomas. VH: variable region of heavy 
chain, DH: diverse variable of heavy chain, JH: joining segment of heavy chain; CH: 
constant region of heavy chain, Vk: variable region of kappa chain, Jk: joining 
segment of kappa chain, Ck: constant region of kappa chain. 
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3.3 Results  
3.3.1 Oxidation of LDL 
The extent of LDL modification by Cu++ ions was estimated by the relative 
electrophoretic mobility of the LDL particles using an agarose gel. The mobility of 
native LDL and LDL oxidized for 4 hour or 24 hours is shown in Figure 3-2.  Figure 
3-3 indicates a time-dependent increase of mobility and an obvious shift, even after 1 
hour of exposure to Cu++. This increase in electrophoretic mobility is due to the 
smaller size of the particles and the more net negative charge resulting from the 
oxidation of LDL (La Belle, et al., 1997). MDA-LDL could not be stained by this 
method.  
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Figure 3-2 Agarose gel electrophoresis of various preparations of LDL. 
The photograph shows the agarose gel electrophoresis of native LDL (lane 1), and 
LDL exposed to CuSO4 (10µM) for 4 hours (lane 2) or 24 hours (lane 3). The 
electrophoretic mobility of the LDL particles increased after exposure to CuSO4 
10µM due to oxidation. Lipoproteins were stained with Coomassie blue. 5µg protein 
was loaded per lane. 
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Figure 3-3 Time course of LDL oxidation 
This graph shows the extent of oxidation of LDL estimated by electrophoretic 
mobility. The relative electrophoretic mobility of LDL after different durations of 
oxidation by Cu++ ions, standardized to non-oxidized LDL (0h). The mobility 
increased almost 2 fold after one hour. Values are mean + SD of triplicates. 
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3.3.2 Cloning of monoclonal autoantibodies  
Monoclonal autoantibodies against OxLDL were generated from a non-immunized 
one year old female LDLr(-/-) mouse after 10 months on a high fat diet. Serum from 
this mouse had an easily detectable level of IgG reacting with copper-oxidised LDL 
(Cu-OxLDL), as detected by ELISA.  
 
Following the fusion of splenocytes from this mouse with the Sp2/0 myeloma cell 
line, cells were plated in a semi-solid selection medium in twelve 10 cm diameter 
Petri dishes. After 14 days of incubation ~2,500 cell clusters survived.  Of these, 950 
were transferred to individual wells for expansion and screening. After 4 days of 
further growth, culture supernatant (150µl) from each well was tested by ELISA to 
detect antibodies reacting with native LDL and/or Cu-OxLDL.  Pooled mouse sera 
from a LDLr(-/-) mouse fed a high fat diet was used as a reference. Ten of the 950 
clones had OD 450 three times as high as that of the blank wells, as shown in Figure 
3-4.  These antibodies were designated with LO (Ldlr knockOut) numbers. Clone 
LO1 had the highest activity against Cu-OxLDL while LO6 and LO9 were the most 
reactive with native LDL. We decided to focus on clone LO1 because of its high 
reactivity to Cu-OxLDL rather than native LDL.  
 
LO1 subcloning was performed twice to ensure monoclonality. Six subclones were 
picked randomly from 255 clones at the end of the second round of subcloning. All 
six subclones that were examined had high reactivity against Cu-OxLDL (Figure 3-5).
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Figure 3-4 Reactivity of antibodies from ten hybridoma clones with LDL and 
Cu-OxLDL 
This figure shows the reactivity by ELISA of culture supernatant of the selected 
hybridoma clones or the pooled sera from LDLr-/- mice (diluted 1:40) against Cu-
OxLDL (black bars) or native LDL (white bars). Clone LO1 had the strongest binding 
to Cu-OxLDL. Values are mean + SD of triplicates. 
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Figure 3-5 Reactivity of LO1 subclones to native LLD and Cu-OxLDL. 
The figure shows the reactivity by ELISA of culture supernatant of subclones of LO1 
to native LDL (white bars) or copper oxidized LDL (black bars). All subclones 
showed strong binding to oxidized LDL. Values are mean + SD of triplicates. 
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Isotypes of clones reacting with Cu-OxLDL.   
Table 3-3 shows the isotype of the three clones with strong reactivity to Cu-OxLDL. 
LO1 has an IgG3 heavy chain while the other two have IgG2b. All three clones have 
kappa light chain. 
 
Table 3-3 The isotypes of selected clones. 
Monoclonal antibody clone Heavy chain Light chain 
LO1  IgG3 Kappa 
LO6 IgG2b Kappa 
LO9 IgG2b Kappa 
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Purification of LO1 and IgG3κ isotype control HK-PEG was performed with protein-
G affinity chromatography column (see page 50). The chromatography denoted a 
single peak. The molecular weight of the heavy chain and light chain were 50kD and 
25kD respectively, as confirmed by SDS-PAGE (Figure 3-6). 
 
 
Figure 3-6 Purification of monoclonal antibodies 
The SDS-PAGE of purified immunoglobulin of LO1, LO9, and IgG3 isotype control 
clone HK-PEG (HK) stained with coomassie blue showed that the molecular weight 
of heavy and light chains are 50k and 25k kD, respectively.  
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3.3.3 Characterization of LO1 
3.3.3.1 Reactivity and Specificity of LO1 
Firstly I compared the binding of LO1 and the other two clones to progressively 
copper-oxidized LDL. LO1-reactive epitopes were formed progressively (Figure 3-7). 
Interestingly clones LO6 and LO9 bound to native LDL preferentially. 
 
 
Figure 3-7 Reactivity of culture supernatant of hybridoma clones  
This graph shows the reactivity of three selected clones to Cu-OxLDL (shadowed 
bars: 4 hours of oxidation; black bars: 16 hours of oxidation) or native LDL (white 
bars). LO1 had strong binding to Cu-OxLDL while clones LO6 and LO9 had strong 
reactivity to native LDL. Values are mean + SD of triplicates. 
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Next, the competitive binding of LO1 in the presence or absence of Cu-OxLDL was 
used to evaluate the specificity of LO1-CuOxLDL interaction (see page 48). The 
added Cu-OxLDL inhibited more than 90% of binding which indicates the binding of 
LO1 to Cu-OxLDL was robust (Figure 3-8).  
 
 
Figure 3-8 Competition ELISA of Cu-OxLDL to LO1-CuOxLDL 
The specificity binding of LO1 to Cu-OxLDL was determined by competition ELISA. 
Fifty µg/ml of Cu-OxLDL almost completely inhibited the binding of LO1 to the Cu-
OxLDL coated on plates. Values are mean + SD of triplicates.  
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The reactivity of LO1 to LDL conjugated with MDA (MDA-LDL) and to 
phosphorylcholine conjugated to BSA (PC-BSA) was measured. The results indicate 
that LO1 also recognizes both MDA-LDL and PC-BSA. On a concentration basis, 
LO1 binds preferentially to MDA-LDL versus Cu-OxLDL and PC-BSA (Figure 3-9).  
 
 
Figure 3-9 The reactivity of LO1 to various antigens associated with oxidised 
LDL. 
Top: The cross reactivity of LO1 (white bars) against Cu-OxLDL, MDA-LDL, and 
PC.  Values are mean + SD of triplicates.  
Bottom: mAb LO1 was titrated on wells coated with 10 µg/ml of various antigens. 
The bound reactivity was detected with anti-mouse IgG. mAb LO1 reacted strongly 
with MDA-LDL and less strongly with PC-BSA and Cu-OxLDL. It did not react with 
native-LDL or BSA (n=3).
 65 
 
Next the binding of LO1 to LDL modified by MDA for different durations was 
examined. LO1 bound with extensively modified LDL better than with mildly 
modified LDL (Figure 3-10).  
  
 
Figure 3-10 mAb LO1 recognizes MDA-LDL 
Top: The extent of the modification to LDL by MDA was estimated by a carbonyl 
assay. The amount of DNP increased with  the length of incubation time. DNP: 2,4-
dinitrophenylhydrazine. 
Bottom: The binding of mAb LO1 or control IgG3 (HK) to LDL modified by MDA 
for varying durations (0-5 hours). LO1 recognizes MDA-LDL in a time-dose 
dependent manner. Values are mean + SD of triplicates. 
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The binding of LO1 to PC-BSA was rechecked in a competition ELISA (with or 
without soluble PC) (Figure 3-11). The binding of LO1 to PC-BSA was not inhibited 
by soluble PC. As a positive control, soluble PC blocked completely the reactivity of 
T15 (an IgA with PC specificity) to PC-BSA.  
 
 
Figure 3-11 Competition ELISA of LO1 binding to PC-BSA 
This graph shows the reactivity of mAb LO1 (20 µg/ml), anti-PC (T15, IgA at 0.1 
µg/ml), and control IgG3 (HK, 20 µg/ml) to a microtiter plate coated with 2 µg/ml of 
PC-BSA. The added soluble PC blocks the binding of T15 to PC-BSA but not the 
binding of mAb LO1 to PC-BSA. 
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Similarly, the binding of LO1 to MDA-LDL was rechecked in competition ELISA 
(with or without soluble PC) (Figure 3-12). The binding of LO1 to MDA-LDL was 
not inhibited by soluble PC.  
 
 
Figure 3-12 Competition ELISA of LO1 binding to MDA-LDL 
This graph shows the reactivity of mAb LO1 (1 µg/ml), anti-PC (T15, IgA at 1 
µg/ml), and control IgG3 (HK, 1 µg/ml) to a microtiter plate coated with 10 µg/ml of 
MDA-LDL. The added soluble PC blocks the binding of T15 to PC-BSA but not the 
binding of mAb LO1 to MDA-LDL. 
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3.3.3.2 The sequencing of the variable region  
The immunoglobulin variable regions of the heavy and the light chains of LO1 were 
sequenced and then examined by BLAST searching NBCI and IMGT databases. The 
heavy chain belongs to VH1 family (VHJ-558) and the light chain to VLII (Vk kn4). 
Neither the heavy nor the light chains of LO1 perfectly matched that of the germline, 
particularly in CDR3 domains (Table 3-4). 
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Table 3-4 Amino acid sequences of variable regions of LO1 
Sequence of variable regions of LO1 heavy chain 
                          <-CDR1->                 <-CDR2->                                     <--CDR3---> 
LO1 VH QVQIQQSRVELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGSGGTNYNEKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCARSFKWKFDY 
VHJ-558 
(AF304553) 
-------GA-----------------------------------------------------------------------------------------ARHSVTTI 
 
 
Sequence of variable regions of LO1 light chain 
                          <CDR1>                 <CDR2>                                 <--CDR3-> 
LO1 VL QNVFTQSPAIMSASPGEKVTMTCSASSSINYMHWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISTMEAEDAATYYCHQRNTYRSR 
Vk kn4 
(AJ235943) 
-I-L-------------------------S------------------------------------------------------------SS-PHS 
 
 
This table shows the reduced amino acid sequences of variable regions of the heavy and light chains of LO1 and their relationship to the most 
homologous germline immunoglobulin available in NCBI and IMGT databases. The differences are highlighted with a bold font. The major 
difference is found in CDR3. CDR: complementarity-determining region.
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3.4  Summary and discussion 
This chapter describes the generation of novel anti-Cu-OxLDL monoclonal antibodies 
for further study. Monoclonal antibodies were cloned from the splenocytes of a naïve 
old LDLr knock out mouse to avoid any artefactual effect of immunisation.   
 
Witztum’s group previously cloned monoclonal anti-Cu-OxLDL antibodies by fusing 
the splenocytes of two non-immunized ApoE(-/-) mice fed a high fat diet with the P3 
myeloma cell line in the late 90s (Palinski, et al., 1996).The protocol we used to make 
monoclonal antibodies was quite similar, except that we used a different strain of 
mouse (LDLr(-/-) ) and a different myeloma cell line (Sp2/0). However, the number 
of harvested hybridomas was markedly different between Witztum’s work and our 
own. In their fusion, 64% of the hybridoma supernatants were reported to react with 
one or more epitopes of OxLDL, although there may have been greater than one 
hybridoma in each well assayed, thus lowering the proportion of positive clones. In 
contrast, only 0.4% (4/960) of my hybridomas secreted anti-OxLDL antibodies.  As 
all the 13 clones that the Witztum group selected were IgM, the most likely reason for 
the lower number of positive clones in this study was that I deliberately screened with 
a gamma chain specific conjugate to obtain IgG antibodies. The variability in immune 
responses between ApoE(-/-) and LDLr(-/-) may also have played a role in the 
difference.  
 
The antibody with the strongest binding to Cu-OxLDL was named LO1. This 
antibody reacted with Cu-OxLDL, MDA-LDL, and PC-BSA whilst lower 
concentrations of mAb LO-1 were needed for more optimal binding to MDA-LDL 
than the amount needed to detect binding to Cu-OxLDL or PC-BSA. Further studies, 
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for example using surface plasmon resonance, are required to make any definitive 
statements about relative affinities. Furthermore, more work is needed to determine 
the nature of LO1 binding to PC, and whether or not this has to be presented in the 
context of BSA. The binding of LO1 to MDA-LDL increased with the duration of 
MDA treatment, suggesting a specificity of LO1 for neoepitopes exposed by MDA 
adduction. However, we do not know the sites of the relevant MDA adduction on the 
apoB-100 protein, and we do not know the optimal numbers of MDA adducts.  The 
binding of LO1 to PC-BSA or MDA-LDL was not blocked by soluble PC, which 
indicated that PC alone was not a sufficiently recognizable site. This is in keeping 
with LO1 being a “group II” anti-PC antibody that develops during the maturation of 
an immune response and reacts with an epitope presented by PC-protein. By contrast, 
germline “group I” anti-PC antibodies (such as T15) react with PC alone (Brown, et 
al., 2000; S. P. Chang, et al., 1982a, 1982b). Even with all these qualifications, LO1 
does appear to differ from previously described anti-OxLDL antibodies such as those 
reacting purely with oxidized phosphatidylcholine (DLH3 (Itabe, et al., 1994), PC 
(EO6, (Palinski, et al., 1996)}) or apoB peptides (4E6 (Holvoet, et al., 1995)). 
 
As with most previous studies in the field, this project used human OxLDL to serve as 
the model auto-antigen. This facilitates an integrated mouse-human approach, with 
the main aim of the study being to develop an assay system that can be used in 
humans. The other major advantage of human OxLDL is its ready availability 
comparing to mouse OxLDL. However, we do not yet know whether LO1 reacts with 
mouse OxLDL, and this remains to be determined. The sequence of human apoB is, 
nevertheless, highly homologous with mouse apoB, and so cross-reactivity is 
certainly possible (Segrest, et al., 1998).  
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LO1 is a mouse IgG3 and there are some interesting analogies between IgG3 and IgM 
as protective antibodies (Y. Han, et al., 2000). IgG3 is reported to be able to self-
associate and act as a polymer, therefore potentially increasing avidity up to that 
obtained by the pentameric structure of IgM (Greenspan & Cooper, 1992). The 
atheroprotective role of natural IgM is now established (Lewis, et al., 2009), and 
similar roles for LO1 and other IgG3 antibodies in atheroprotection deserve further 
studies. 
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CHAPTER 4 Results II: cloning and characterization of 
anti-idiotype antibodies  
4.1 Chapter Introduction 
Having obtained a monoclonal antibody, LO1, against oxidised LDL, I set out to use 
this to generate an anti-idiotype that might act as a surrogate antigen of OxLDL. In 
this chapter, I describe how I selected, screened, produced, purified, and examined 
anti-LO1 idiotype antibodies (anti-id) derived from a human scFv library. The 
homology between an anti-id scFv that I obtained and apoB peptides or PC is 
analyzed in section 4.3.3. 
 
4.2 Methods and materials 
4.2.1 The Tomlinson I phage library and its management 
The Tomlinson I library (Medical Research Council, Cambridge, UK) is a non-
immunized human scFv phagemid library that was constructed in pIT2 (HIS6 myc 
tag) from synthetic VH (V3-23/DP-47 and JH4b) and Vκ (O12/O2/DPK9 and Jκ1) 
with side chain diversity. The diversified residues were based mainly on positions that 
are diverse in the primary repertoire and which are known from crystallographic 
studies to make contact with antigen. These are: H50, H52, H52a, H53, H55, H56, 
H58, H95, H96, H97; L50, L53, L91, L92, L93, L94, L95, and L96. The total 
diversity of each library is about 1.4 x 108 (Goletz, et al., 2002) (de Wildt, et al., 
2000). The functional scFvs bind both protein A, and protein L, and either one of 
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these or the myc or 6 histidine (HIS6) tags can be used for detection, purification or 
immobilization.  
 
The phagemid-containing TG1 (T-phage resistant E. Coli) cells were amplified in a 
2xYT microbial medium (Sigma Y2627) containing ampicillin (100 µg/ml) (Sigma 
A2804) and glucose (1%, w/v) and grown with shaking at 37°C until the OD600 was 
about 0.4. The exponentially grown library-containing TG1 was then infected with 
KM13 helper phage and selected by ampicillin (100 µg/ml) and kanamycin (50 
µg/ml, SigmaK0129). The expanded phagemid library was then precipitated with 
PEG/NaCl (20% w/v polyethylene glycol 6000, 2.5 M NaCl) precipitation and titered 
on TYE plates (15 g Bacto-Agar, 8 g NaCl, 10 g Tryptone, 5 g Yeast Extract in 1 L 
dH2O) containing ampicillin (100 µg/ml) and glucose (1%).  
 
4.2.2 Phage Selection by LO1 
Prior to positive selection of LO1-specific binding phages with mAb LO1, the library 
was depleted of irrelevant phages by pre-absorption with blank magnetic beads and 
then with beads conjugated with isotype-matched control IgG3 HK-PEG-1 (European 
Collection of Cell Cultures, accession number 90112229).  
  
Purified monoclonal antibodies (LO1 or HK-PEG-1, 1.5 µg/200 µl beads in the first 
round, 1 µg/200 µl in the second and third rounds) were coated on mouse-IgG(Fc)-
specific magnetic beads (monoclonal human anti-mouse IgG antibody, Invitrogen, 
cat# 110.41) for 2 hours at RT. After washing with 0.05 % tween-PBS, the beads 
were blocked with 3% BSA/PBS for 1 hour at RT. All tubes were also pre-blocked 
with 3% BSA/PBS. 
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5x1012 PFU of the phagemid library were pre-incubated with uncoated magnetic 
beads and 3% BSA/PBS for 1 hour at RT. The unbound library was then biopanned 
using the irrelevant isotype-matched monoclonal antibody HK-PEG before each 
round of selection panning (Figure 4-1). 
 
In the first round, the beads were washed with 1% BSA/PBS 10 times, then with PBS-
tween 10 times, and in the second and third rounds with PBS-tween for 15 and 20 
times, respectively. In each selection the beads were finally washed with PBS before 
the phages were eluted, as described below. 
 
Trypsin was used to elute phages (1 mg/ml in PBS) for 15 minutes at RT, after which 
phages were transferred to a new blocked tube. Eluted phages were used to infect 
logarithmic grown TG1 (OD600 about 0.4) by incubating at 37°C in a water bath 
without shaking. One tenth of the infected TG1 were then titrated in serial 10-fold 
dilution for phage titrating. The remaining infected TG1 were spread on a 15cm x 
15cm TYE plate containing ampicillin 100µg/ml and grown at 37°C overnight. 
 
Phagemid-containing bacteria were scraped from the agar surface into 2TY media 
containing ampicillin (100 µg/ml) and glucose (1%) and grown at 37°C with shaking 
until OD600 reached 0.4. The propagated phagemid was then rescued by MK13 helper 
phage and precipitated with PEG/NaCl (20% (w/v) polyethylene glycol 6000, 2.5M 
NaCl). The phagemid product then was ready for titrating and for the next round of 
selection. 
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Figure 4-1 The diagram of phage selection 
The phage library was pre-cleared to remove phages reacting with isotype control 
IgG3. The pre-cleaned library then was bio-panned with LO1 and non-bound phages 
were washed thoroughly. Finally the bound phages were eluted and propagated for the 
next round of panning.  
4.2.3 The screening of phage clones 
After each round of selection, 95 colonies on titrating plates were randomly chosen 
and grown in 100 µl 2xYT containing 100 µg/ml ampicillin and 1% glucose in 
microtiter plates for propagation. Phage-containing culture supernatants were used 
directly for screening phages by ELISA. The ELISA plates were coated with LO1 or 
control IgG3 (10 µg/ml in PBS) overnight at 4°C and were then blocked with 2% 
BSA/PBS for 2 hours at RT. 10 µl PEG precipitated phage in 100µl of 2% BSA/PBS 
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was added into each well for 1 hour of incubation. After 3 washes with PBS-tween, 
the bound phage was probed by HRP-anti-M13 antibody (a monoclonal antibody that 
reacts specifically with the phage M13 major coat protein product of gene VIII, 
1:5000, GE cat# 27-9421-01) and TMB substrate. Phages giving an OD450 in mAb 
LO1 coated wells three times higher than those in the control IgG3 coated wells were 
considered to be specifically reactive with mAb LO1. 
4.2.4 Sequencing phage clones 
All clones positive in the ELISA screen were sequenced. Phagemid double stranded 
DNA was purified by miniprep kits (Qiagen cat# 27104) and subjected to sequencing 
on an automated ABI3730 sequencing system operated by Imperial Central 
Sequencing Service. The primers used for sequencing were: 
For VH: CGA CCC GCC ACC GCC GCT G 
For Vκ: CTA TGC GGC CCC ATT CA (made by MWG-biotech, Germany).  
The data was analyzed with open source software eBioX. 
(http://www.ebioinformatics.org/ebiox/). Sequence-comparisons of the CDR regions 
of the H3 anti-idiotype with human and mouse apolipoprotein B-100 (Swiss-Prot: 
P04114.1) was performed with Clustal W algorithm to create multiple alignments.  
 
Nilsson and colleagues reported that seven segmented peptides of human apoB 100 
bind serum antibodies of patients with atherosclerosis (Fredrikson, et al., 2003). Using 
these peptides as potential functional epitopes of OxLDL, they were compared with 
H3. These seven peptides are: P32: GNMGQTMEQLTPELKSSILK; (466-485)  
P45: IEIGLEGKGFEPTLEALFGK; (661-679) 
P102: SLTSTSDLQSGIIKNTASLK; (1531-1549)  
P129: GSTSHHLVSRKSISAALEHK; (1921-1939) 
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P162: IREVTQRLNGEIQALELPQK; (2416-2435) 
P210: KTTKQSFDLSVKAQYKKNKH; (3135-3154) 
P240: FPDLGQEVALNANTKNQKIR (3585-3604). 
 
The peptide mimic of PC was analyzed, where the sequence used in the homology 
analysis is ASRNKANDYTTEYSASVKGRFIVS, as reported by Kang (Kang, et al., 
1988) and Harris (Harris, et al., 2000). 
4.2.5 Production of soluble antibody fragments 
As the TAG stop codon was suppressed in TG1 E. Coli, both scFv and PIII were 
expressed while the overall level of scFv production decreased. Colonies of phage 
were selected and transferred individually to HB2151 (a non-suppressor strain) which 
was able to produce a higher level of soluble antibody fragment. 
 
The infected HB2151 was then grown and induced with 1mM IPTG (isopropyl β-D-
thiogalactoside, Sigma cat# I1284). The pIT2 construct had a HIS6 tag so that the 
antibody segments could be purified with a nickel purification system. scFv was 
therefore bound to Ni-NTA agarose (Qiagen, cat# 30210) then eluted by 250 mM of 
imidazole. The purity and intactness of the protein were examined with an SDS-
PAGE stained with Coomassie blue and His-tag In-gel Staining kit (Invitrogen cat# 
LC6033). 
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4.3 Results 
4.3.1 Selection of human scFv against OxLDL-reactive monoclonal antibody 
LO1 
4.3.1.1 Selection 
Affinity-purified monoclonal anti-OxLDL LO1 was used to select ligands from an 
unbiased phage library displaying human scFv antibodies (Tomlinson I). The 
selection of scFv anti-LO1 was carried out in three rounds, and then the selected 
phages were sequenced. The results of ELISA and gene diversity of the three rounds 
are shown in Table 4-1. After two rounds of panning, a minimal enrichment (3.6-fold) 
of phage titres was observed. 
 
Table 4-1 Enrichment of scFv clones from Tomlinson I library in three panning 
rounds  
Round Phage input 
(cfu/ml)a 
Phage output 
(cfu/ml) b 
Ratio 
(output/input) 
Phage 
enrichment c 
1 2 x 1012 2.8 x 106 1.4x10-6 Not available 
2 1 x 1010 5 x 104 5x10-6 3.6 
3 5 x 109 2.5 x 104 5x10-6 1 
a: Phage input means the titre of the phage applied in the panning round. 
b: Phage output means the titre of the phage elute of the panning round. 
c: Phage enrichment is the quotient of the output/input ratio of one round divided by 
that of the previous round. Therefore, round 1 does not have any such value. 
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After the first round of selection, none of the 95 clones reacted to LO1. After the 
second round, nine of the 95 clones were positive in ELISA screening, and there were 
4 different sequences among these 9 clones. In the third and final round, all of the 10 
ELISA-positive clones had the same sequence, indicating that the diversity converged 
rapidly in this round of selection (Table 4-2).  
 
Table 4-2 The reactivity to mAb LO1 and sequence diversity of three rounds of 
phage panning 
Selection ELISA 
LO1(+) control IgG3(-) 
Diversity 
Different sequences # / sequenced clones. 
1st round 0/95 - 
2nd round 9/95 4/9  
3rd round 10/95 1/10 (this clone was named as H3) 
 
The rate of positive to LO1 was similar between the 2nd and 3rd rounds. The genetic 
diversity of CDR of scFv, however, converged to only a single clone. These selected 
clones were designated with H numbers. The final predominant clone was H3, and 
this was used for further characterisation. 
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4.3.1.2 Production of scFv 
The integrity of affinity purified scFv was determined by SDS-PAGE. Coomassie 
blue staining revealed the correct size of purified scFv (30 kD) (Figure 4-2 top). 
HIS6-tag staining also demonstrated intact protein with the right size. (Figure 4-2 
bottom) 
 
 
 
Figure 4-2 The purity of obtained scFv. 
SDS-PAGE of purified scFv was stained with coomassie blue (top) or HIS6 tag 
staining (bottom). Columns 1, 3, 5, 7 are culture supernatant. Columns 2, 4, 6, 8, 9 are 
purified scFv(s). The estimated molecular weight of svFv is 30kD. M: markers. 
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4.3.2 Specificity of scFv binding 
The dominant and highly reactive phage clone (H3) from the final round of selection 
was analyzed further in terms of specificity and binding strength toward LO1 in a 
capture ELISA. Both monoclonal phage particles and purified H3 scFv bound to LO1 
but not to HK (control IgG3). Reference phages, used as negative control scFv, 
showed no LO1-specific binding to immobilised LO1 (Figure 4-3). 
 
 
Figure 4-3 Binding of H3 scFv to mAb LO1.  
Microtiter plates were coated with mAb LO1 or control IgG3. Purified H3 scFv 
bound to LO1 but not to control IgG3. Compared with control IgG3, negative control 
scFv showed no specific binding to LO1. Values are expressed as mean ± SD  
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The capacity of H3 to neutralise mAb LO1 was examined by competition ELISA. The 
reactivity of mAb LO1 to PC-BSA was measured with or without H3. Figure 4-4 
shows that the binding of mAb LO1 to PC-BSA was inhibited by H3, but not by 
control scFv. This observation supports the notion that H3 and PC-BSA share a 
common epitope that is recognised by LO1.  
 
Figure 4-4 Competition ELISA of mAb LO1 binding to PC-BSA 
This graph shows the reactivity of LO1 (2 µg/ml) and control IgG3 (2 µg/ml) to a 
microtiter plate coated with 10 µg/ml of PC-BSA. The added H3 scFv, but not control 
scFv, blocks the binding of mAb LO1 to PC-BSA. Values are expressed as mean ± 
SD. 
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Similarly, the reactivity of mAb LO1 to MDA-LDL was measured with or without 
H3. Figure 4-5 shows that the binding of LO1 to MDA-LDL was inhibited by H3 but 
not by control scFv. This observation is consistent with H3 and MDA-LDL also share 
a common epitope that is recognised by LO1. The IC50 of H3 for inhibiting mAb 
LO1 binding to PC-BSA and MDA-LDL was similar (0.8-4.0 µg/ml). 
 
 
Figure 4-5 Competition ELISA of LO1 binding to MDA-LDL 
This graph shows the reactivity of LO1 (2 µg/ml) and control IgG3 (2 µg/ml) to a 
microtiter plate coated with 10 µg/ml of MDA-LDL. The added H3 scFv, but not 
control scFv, blocks the binding of LO1 to MDA-LDL. Values are expressed as mean 
± SD  
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4.3.3 Analysis of scFv sequences 
The amino acid sequences of the selected clones are listed in Table 4-3. H3 has a 
sequence distinct from other LO1-reactive H series clones, especially in the heavy 
chain. H3 CDR sequences were compared separately with the linear sequence of 
human apoB-100 using Clustal W algorithm. VH CDR2 of H3 has 11 amino acid 
identity of total 17 residues with apoB-100 amino acids 1364-1378; VH CDR3 
matched four identical and one similar residues in amino acid 3988-3995; VL CDR2 
matched with five identical and one similar amino acids at 1521-1528; VL CDR3 
matched five in nine amino acids of 2555-2562 (Table 4-4, page 87). The CDR2 
regions have better homology to apoB sequences than the CDR3 sequences. From the 
linear sequence of H3, CDR2 seems to be the main apoB mimetic site (Figure 4-7, 
page 89). It should be noted, however, that the region in the VL CDR2 with 
homology to ApoB amino acids 1521-1528 is constant in the scFv library, and 
therefore is unlikely to be sufficient for mAb LO1 binding.  
 
The ApoB peptide sequences delineated above as similar to the four H3 CDR 
sequences were compared with the seven peptides of apoB-100 identified with human 
serum antibodies by Nilsson’s group (Fredrikson, et al., 2003). Surprisingly, the 
sequence with similarity to VL CDR2 of H3 is matched with P102, which was 
reported by Nilsson as being related with human atherosclerosis (Figure 4-6, page 
88).  
 
Eight of 12 amino acids in the VH CRD2/FR3 conserved region of the Tomlinson 
library are the same as the PC mimetic and self-binding site of T15 (Figure 2-1, page 
43) (Kang, et al., 1988) (Harris, et al., 2000). 
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Table 4-3 Amino acid sequences of the selected scFv(s). 
 Heavy chain                                         <CDR2           >                                <CDR3  > 
H3 AMAEVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSDISGSGNTTTYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDDDAFDYWG 
H1 ----------------------------------------------------T-ANN-YS-N---------------------------------------TAT------ 
H6 ------------------------------------------------------AYG-TN-N---------------------------------------GST------ 
H7 ----------------------------------------------------A-GYG-TS-A---------------------------------------GTS------ 
Control -------------------------------------------------------AG-YS-----------------------------------------STY------ 
 
 Light chain                                         <CDR2   >                              <CDR3   >       
H3 GSTDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYYASALQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDAAPTTFGQGTKVEIK 
H1 ----------------------------------------------------S—-N------------------------------------------Y----------- 
H6 ----------------------------------------------------D--D----------------------------------------G------------- 
H7 ----------------------------------------------------D--D----------------------------------------G------------- 
Control ----------------------------------------------------T--Y--------------------------------------SGSS------------ 
This table shows the sequences of the variable regions of the selected scFv. The differences of other LO-1 reactive H clones from clone H3 are 
printed in letters. The hyper-mutated positions within scFv in the library are shaded in gray in the H3 sequence. A negative control scFv which 
did not bind to LO1 is shown for comparison, as this scFv served as a negative control in some other experiments. Dashes denote identical 
residues. 
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Table 4-4 Homology between CDR regions of H3 and ApoB and PC mimetic site of T15. 
Heavy chain VH CDR2 VH CDR3  
H3   DISGSGNTTTYADSVKGRFT DDDAFDYW 
Human ApoB   NVQ---E--YD E—-D-SK- 
Mouse ApoB   SVQ---E--YD G-GKLSF- 
PC mimetic site of T15          --E-SA------I  
Tomlinson library structure (* 
denotes hypervariable residuals) 
  *-***-**-*---------- 
            CDR2--><FR 
 
 
Light chain VL CDR2 VL CDR3 
H3 YASALQSGV QQGDAAPTT 
Human ApoB ST-D----I E—-FTV-EI 
Mouse ApoB ST-D----I R-M—-IDV- 
The homology between CDRs of scFv and human ApoB, mouse ApoB, the PC mimetic and self-binding site of T15, and the backbone of 
Tomlinson library is shown. Those residues present in the CDRs that are identical or similar to amino acids of ApoB-100 or PC mimetic site are 
indicated in bold, and those that are physicochemically related amino acids are drawn in bold-italics. The gray shaded sites denote good matches 
with apoB. The boxed site denotes a good match with the PC mimetic and self-binding site of T15. The CDR2 of H3 heavy chain has an 
extraordinary similarity to an ApoB protein sequence adjacent to the sequence of the PC binding site of T15. Dashes denote identical residues. 
Swiss-Prot ID of human ApoB-100: P04114.1, mouse ApoB-100: Q3UH74. 
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Figure 4-6 Homology between CDRs of scFv H3 and Nilsson’s seven peptides  
This schema shows the homology between the apoB peptides identified as similar to CDRs of H3 (as in Figure 4-5) and the seven peptides 
related with carotid IMT that were reported by Nilsson’s group (Fredrikson, et al., 2003), which are marked as blank boxes. The white boxes 
denote CDRs of scFv H3. The CDR2 of light chain matches well with P102 (AA 1530-1549). 
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Figure 4-7 Schema of H3 sequence mimic apoB segments and PC 
This graph shows the structure of scFv H3. The CDR2s are the major mimetic sites of epitopes expressed on apoB. ApoB (p102) is one of the 
short peptides that Nilsson et. al reported to be related to atherosclerosis (Fredrikson, et al., 2003) (also see Figure 4-6). PC: phosphorylcholine.  
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Two interesting sequences were noted in LO1 CDRs that may be relevant to binding 
H3. First, a simple charge analysis provides potential complementarity between CDRs 
of LO1 and those of H3. In fact the positively charged Rs in LO1 VL CDR3 
(HQRNTYRSR) could interact with the negatively charged Ds of H3 VHCDR3 
(DDDAFDYW). Second, the LO1 VH CDR3 ARSFKWKFDY is strikingly similar to 
the complementary sequence ASRNKANDYTT that Kohler proposes binds 
SASVKGRFIVSR in the PC-mimetic and self-binding region of T15 CDR2/FR3 
(Figure 2-1) (Zhao, et al., 2005).  
 
4.4 Summary and discussion 
In this chapter I presented data showing how I identified several different scFv clones 
with anti-idiotypic specificity for anti-LO1. One dominant clone, H3, was further 
characterized. H3 scFv bound to mAb LO1, but not to control IgG3. H3 also 
completely inhibited the binding of LO1 to MDA-LDL or PC-BSA, which supports 
the possibility that it recognises the antigen-binding sites on LO1. Finally, the 
sequence of CDRs of H3 was compared with those of human apoB and mouse apoB 
to examine the homology between the anti-idiotype and the original Ag. 
 
Perhaps surprisingly, there was homology between the CDR sequences of H3 and 
sequences of apolipoprotein B (both of human and mouse). Furthermore, the sequence 
of CDR2 of H3 heavy chain matches well with that of a peptide mimic of PC (Table 
4-4). These sequence similarities we have discovered suggest that mAb LO1 may 
recognise a conformational epitope involving peptide and lipid (i.e. PC). In further 
support of mAb LO1 recognising a conformational epitope is our failure to 
demonstrate recognition of oxidised LDL by LO1 using western blotting (not shown). 
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Whilst the sequences of H3 that have similarity to apoB peptides reflect diversity 
within the CDRs of different antibodies within the scFv library, the PC-mimetic 
region is found on the junction of CDR2 (VH) and framework 3 (FR3), reflecting the 
choice of the human V3-23 gene for constructing the scFv library. Also, the 
CDR2/FR3 region of human V3-23 is highly homologous to the comparable region in 
mouse T15 involved in PC-binding and self-binding (Harris, et al., 2000) (Zhao, et al., 
2005) (Table 4-5). If this is the site on H3 that mimics PC, the fact that not all scFv in 
the library bind to LO1 indicates that the sequence is not sufficient for allowing LO1 
binding under the experimental conditions we used. Considering the involvement of 
this peptide sequence in T15 antibody self-binding, a further interesting possibility 
that comes out of our observations is that mAb LO1 may bind to T15 antibodies, but 
this has not yet been experimentally tested. If this is so, mAb LO1 could have the 
capacity to limit T15 antibody aggregation. 
 
Table 4-5 Homology between Tomlinson library and mouse T15 CDR (VH). 
Human V3-23 (Tomlinson library) TTTYADSVKGRFTISRDNSKNTLYLQMNSLRA 
Mouse T15 family (GenBank: 
AH003512.1) 
Y--E-SA------IV---T-QSI------A-- 
 
A closer look at the similarity between the sequences of H3 and apoB revealed that 
the CDR2 (VL) of H3 closely matched peptide P102, which, reported Nillson’s group, 
correlated with atherosclerosis. Dashes denote identical residues. (Fredrikson, et al., 
2003) (Figure 4-6). 
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Two novel observations about peptide mimicry can be made from this analysis. First, 
although many anti-idiotypic antibodies have structural similarity to self-antigen 
(Vogel, et al., 2000), there have been no published observations of this nature in the 
field of atherosclerosis. Secondly, the sequence spanning VH CDR2/FR3 of anti-id 
H3 has good homology to both apoB peptide and PC. To my knowledge, the 
molecular definition of dual reactivity of an antibody to both protein and phospholipid 
determinants has not been reported previously. The exact immunogenic function of 
CDR regions of H3, however, needs further experimental characterization to be 
narrowed down and proven. At this stage, however, I chose to test whether the whole 
H3 molecule could be used as an antigen in serological assays. 
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CHAPTER 5 Results III: antibodies reacting with OxLDL 
and H3 in mice 
5.1 Chapter Introduction 
The anti-id scFv H3 that was developed and discussed in Chapter 4 binds specifically 
to LO1, and contains both apoB and PC mimetic sequences. It occurred to us that 
using this anti-id scFv in serologic assays would provide a more defined and stable 
antigen than OxLDL (see tables in section 2.4, page 31 to 38).  
 
In section 5.2 I describe the materials and methods used in the assays. The antigens 
that have been previously tested in the thesis are Cu-OxLDL, MDA-LDL, PC, and 
H3. Sera of mice of different ages, strains (wild type vs. LDLr(-/-) ), and diet (low vs. 
high fat diet) were used for various ELISA. The trend of antibody titres between these 
variables is recorded in section 5.3. Most importantly, the correlations between anti-
H3 antibodies and other relevant antibodies are analyzed in section 5.4. 
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5.2 Methods and materials 
5.2.1 Maintenance of animals 
Low-density lipoprotein receptor deficient (LDLr-/-) mice on a C57BL/6 background 
were bred in-house. Wild type C57BL/6 mice were purchased from Harlan 
Laboratory. All animals were housed under specific-pathogen free conditions with 
sentinel mice periodically checked for infections. All animals were studied according 
to UK Home Office regulations. Only female mice were used in this study to avoid 
the interference of gender. The mice bred in-house were weaned at 4 weeks of age 
and maintained on a normal chow diet. When indicated, the normal chow diet was 
gradually replaced at 6 weeks of age by either a high-fat diet (Hope Farms, cat# 
4021.06, Woerden, Netherlands) or a low-fat reference diet (Hope Farms, cat# 
4068.02) until sacrifice. 
5.2.1.1 Composition of special diets: 
The composition of the high-fat diet (w/w) used in this study is cocoa butter (15%), 
cholesterol (0.25%), sucrose (40.5%), cornstarch (10%), corn oil (1%), cellulose 
(5.95%), casein (20%), 50% choline chloride (2%), methionine (0.2%) and mineral 
mixture (5.1%). The low-fat diet comprised dextrose (54.3%), soya oil (5%), 
cornstarch (10%), cellulose (5%), casein (20%), 50% choline chloride (0.4%), 
methionine (0.2%) and mineral mixture (5.1%). 
 
5.2.2 Serum collection  
Terminal blood was obtained from cardiac puncturing and centrifuged at 13,000 rpm 
for 30 minutes. The supernatant was then collected and frozen at -80°C until use. 
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5.2.3 ELISA for H3, modified LDL, or PC 
The ELISAs used to test mouse sera were similar to those used in hybridoma 
screening. Maxisorb 96-wells plates were coated with 50 µl (10µg/ml) of LDL 
antigens (Cu-OxLDL, MDA-LDL, or native LDL) or scFv (H3 or negative control 
scFv at 10µg/ml) or PC-BSA (5µg/ml) in PBS at 4°C overnight. Non-adherent 
material was washed out, and then the plates were blocked with 2% BSA/PBS for 1 
hour at RT. Appropriately diluted serum or non-diluted mAb LO1 culture supernatant 
was added for incubation for 1 hour at RT. The dilution was determined by 
preliminary serial dilution experiments to get the maximal signal/background value 
(Table 5-1). Then wells were incubated with biotin-conjugated goat anti-mouse IgG 
(Southern biotech, cat# 1030-08) or IgM (Southern biotech, cat# 1020-08), followed 
by streptavidin-HRP (R&D, DY998). The final signal was detected with 3,3,5,5-
Tetramethylbenzidine (TMB) (Sigma, Cat# T0440) and the reaction stopped with 
0.5M H2SO4 after 10 minutes. The optical density was measured with a Synergy HT 
microplate reader (Biotek, USA) at wavelength 450nm. 
 
All samples were measured in triplicate wells. The measurements from the wells 
coated with native LDL or control scFv were subtracted as background in anti-
OxLDL and anti-H3 ELISAs respectively. Plate-to-plate variability was corrected by 
checking LO1 reactivity at 1µg/ml and using several control samples (two batches of 
pooled selected serum with high reactivity) on all plates as references. This variability 
was less than 10% in all eight assays. All the reported OD in this assay was corrected 
by these control samples. The reproducibility of the assays was assessed by repeated 
measurements, and the coefficient of variation was determined to range from 4 to 
12%. 
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Table 5-1 Dilutions of mouse sera in ELISAs 
ELISA IgM IgG 
H3 100 100 
MDA-LDL 200 100 
Cu-OxLDL 50 100 
PC 100 100 
 
5.2.4 Statistical analyses 
Values are expressed as median (25th, 75th percentile). The Mann-Whitney U test 
was used to compare the levels of antibodies in two groups. The Kruskal-Wallis test 
with Bonferroni correction was used to compare the level of antibodies in the 
different age groups. Pearson correlation was used to estimate the association between 
different antibodies. The statistical significance was set at the 0.05 level. The 
statistical software used are Prism 4.0 (GraphPad, La Jolla, CA) or Stata 9.0 (College 
Station, Texas). 
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5.3 ELISA of anti-H3, Cu-OxLDL, MDA-LDL, and PC antibodies 
Sera were collected by cardiac puncture at the ages of 6, 20, 40 and 60 weeks old, in 
order to determine changes with age in immune responses to the surrogate antigen H3 
and to Cu-OxLDL, MDA-LDL, and PC. The difference between two strains (i.e. 
LDLr(-/-) versus wild type) and between two diets (i.e. low fat versus high fat diet) 
were also measured. IgM or IgG anti-H3, Cu-OxLDL, MDA-LDL, and PC of 11 
groups are displayed in Figure 5-1. All antibodies were readily detectable except IgG 
anti-PC, which was found in only a few elderly wild type mice. 
 
The mice were divided into three groups: wild type fed with low fat diet (coded B), 
LDLr(-/-) fed with low fat diet (coded L), and LDLr(-/-) fed with high fat diet (coded 
H). LDLr(-/-) mice were fed high fat diet from 6 weeks of age, so the 6-week old 
mice in group L were also used as control for LDLr(-/-) mice fed with high fat diet 
(group H), The sample size in each group was 7 or 8. 
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(A)      (B) 
 
(C)      (D) 
 
(E)      (F) 
 
(G)      (I) 
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Figure 5-1 Level of antibodies in different groups of mice. 
The charts on the previous page show IgM (left) and IgG (right) against H3, MDA-
LDL, Cu-OxLDL, and PC-BSA. Legend of X-axis: B: BL6 (wild type C57BL/6) fed 
with low fat diet, L: LDLr(-/-) fed with low fat diet, H: LDLr(-/-) fed with high fat 
diet after 6 weeks. The number indicates age; e.g. B20W means 20 week old BL6 
strain. IgG anti-PC were barely detectable in all groups. N=7 or 8 in each group. 
Group means are expressed as horizontal bars. The units of the y-axis are corrrected 
OD450 values. The values were corrected as described in Section 5.2.3. 
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5.3.1 Univariate analysis 
The statistical analysis of strain, diet, and age is shown in Table 5-2. Generally 
speaking, age was the main determinant in most of the ELISAs. 
 
5.3.1.1 Anti H3 
The temporal expression patterns of IgM antibodies against H3 in wild type and 
LDLr(-/-) were similar. The level of IgM anti-H3 was significantly higher than that in 
6-month-old mice whose IgM anti-H3 level grew with age until 20-week-old and held 
steady until 60 weeks old (Figure 5-1-A and Table 5-2). Strain and diet did not make 
any difference, implying that the steady levels of anti-H3 IgM antibodies were not 
affected by hypercholesterolemia. IgG anti-H3 had a similar temporal pattern to that 
of IgM anti-H3, with no differences observed between different diets or strains 
(Figure 5-1-B).  
 
5.3.1.2 Anti Cu-OxLDL 
IgM anti-Cu-OxLDL of LDLr(-/-) mice at 6 weeks was higher than that of older mice. 
However, there was no difference between all other ages, strains, or diets (Figure 5-1-
C). The temporal pattern of IgG anti-Cu-OxLDL was exactly the same as that of anti-
H3 IgG: the level of IgG anti-Cu-OxLDL in 6-week old mice was significantly lower 
than that in older mice (Table 5-2). No differences were observed between strains or 
diets (Figure 5-1-D). 
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5.3.1.3 Anti MDA-LDL 
Mice fed with low fat diet had a similar pattern of IgM and IgG anti-MDA-LDL: the 
level of IgM anti-MDA-LDL in 6-week old mice was significantly lower than that in 
older mice. However, mice given a high fat diet showed no such trend (Figure 5-1-E). 
The only obvious clustering of IgG anti-MDA-LDL was the lower level in the 6-week 
old mice. No differences were observed between strains or diets (Figure 5-1-F). 
5.3.1.4 Anti-PC 
There was a progressive decrease of serum IgM anti-PC in LDLr(-/-) fed with low fat 
diet (Figure 5-1-G, group L). In groups B (wild type fed with low fat diet) and group 
H (LDLr(-/-) fed with high fat diet), however, there was an opposite trend, although 
neither was statistically significant (Figure 5-1-G). Wild type mice had higher IgM 
anti-PC than LDLr(-/-) mice when evaluated globally. Similarly, mice fed with low 
fat diet had more IgM anti-PC than those fed with high fat diet (Table 5-2). IgG anti-
PC was barely detectable in our system except in just few wild type mice (Figure 5-1-
I).  
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IgM  H3 25% Med 75%  25% Med 75% p  
Strain WT 0.26 0.48 0.76 KO 0.46 0.31 0.63 0.45  
Diet LF 0.31 0.49 0.75 HF 0.27 0.46 0.62 0.42  
Age 6w 0.14 0.2 0.26 40w 0.42 0.48 0.63 0.0001 
6w<20w, 
6w<40w, 
6w<60w 
 20w 0.31 0.47 0.74 60w 0.43 0.65 0.91   
IgG  H3          
Strain WT 0.12 0.56 0.76 KO 0.43 0.83 1.2 0.023 KO> WT 
Diet LF 0.35 0.65 1.14 HF 0.38 0.83 0.96 0.76  
Age 6w 0.1 0.11 0.16 40w 0.59 0.83 1.11 0.0001 
6w<20w, 
6w<40w, 
6w<60w, 
20w<60w 
 20w 0.38 0.53 0.84 60w 0.72 1.03 1.57   
IgM  
Cu-
OxLDL          
Strain WT 0.58 0.77 0.94 KO 0.55 0.82 1.06 0.58  
Diet LF 0.55 0.77 0.94 HF 0.66 0.85 1.07 0.23  
Age 6w 1.04 0.84 1.54 40w 0.59 0.74 0.88 0.002 
6w>20w, 
6w>40w, 
6w>60w   
 20w 0.56 0.82 0.93 60w 0.41 0.7 0.94   
IgG 
Cu-
OxLDL          
Strain WT 0.12 0.52 0.73 KO 0.46 0.63 0.83 0.1  
Diet LF 0.25 0.55 0.74 HF 0.48 0.64 0.87 0.08  
Age 6w 0.07 0.09 0.11 40w 0.46 0.72 0.89 0.0001 
6w<20w, 
6w<40w, 
6w<60w 
 20w 0.47 0.58 0.71 60w 0.58 0.73 0.94   
IgM 
MDA-
LDL           
Strain WT 0.45 0.61 0.87 KO 0.59 0.76 0.9 0.11  
Diet LF 0.51 0.72 0.94 HF 0.5 0.71 0.81 0.33  
Age 6w 0.32 0.38 0.48 40w 0.6 0.74 0.9 0.0007 
6w<20w, 
6w<40w, 
6w<60w 
 20w 0.57 0.7 0.85 60w 0.64 0.83 1.1   
IgG 
MDA-
LDL          
Strain WT 0.56 0.9 1.1 KO 0.73 0.94 1.2 0.3  
Diet LF 0.67 0.93 1.2 HF 0.74 1.1 1.25 0.26  
Age 6w 0.16 0.46 0.68 40w 0.73 0.98 1.4 0.0002 
6w<20w, 
6w<40w, 
6w<60w 
 20w 0.7 0.92 1.19 60w 0.92 1.1 1.22   
IgM PC          
Strain WT 0.66 0.87 1.1 KO 0.41 0.66 0.95 0.023 WT > KO 
Diet LF 0.54 0.79 1.1 HF 0.42 0.59 0.85 0.036 LF > HF 
Age 6w 0.57 0.77 1.41 40w 0.72 0.78 0.99 0.41  
 20w 0.47 0.69 1.08 60w 0.38 0.67 0.89   
Table 5-2 Univariate analysis of seven ELISA in mouse sera 
The variables reaching statistical significance (by Mann-Whitney test) are listed in 
bold. Med: median, WT: wild type, KO: LDLr knock out, LF: low fat diet, HF: high 
fat diet, w: week, PC: phosphorylcholine 
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5.3.2 Multiple-variable analysis 
The univariate analysis described in the previous section did not consider the 
interaction between predictors. Therefore, multiple regression models are essential for 
elucidating this issue and for unmasking the real correlations. Age, strain, and diet 
were entered into a multi-regression model to identify independent predictors for 
antibodies. A variable that gave a positive coefficient indicates that it predicted a 
higher level of antibodies. The adjusted r2 estimates the explanatory ability of the 
model. (Table 5-3). 
 
Diet and age were two independent predictors of anti-H3 IgM. The fitness of the 
model using these two predicators, however, was not great. (Adjusted r2=0.33). Strain, 
diet, and age were three independent predictors for anti-H3 IgG. The model using 
these three predicators showed an adjusted r2= 0.48, meaning that these 3 variables 
might predict about half of the observations. Age is the sole major determinant for 
IgM anti-Cu-OxLDL. (Adjusted r2=0.46). 
 
For IgM anti-Cu-OxLDL, anti MDA-LDL IgG and IgM, there were various 
parameters that reached statistical significance. Their adjusted r2, however, were quite 
low (<0.3). In the regression model for IgM anti-PC, none of the three variables was 
an independent predictor.  
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 Variables Coefficient Standard 
Error 
p-value Adjusted r2 
IgM anti-H3     0.33 
 High fat diet -.13 0.06 0.023  
 Age 0.35 0.07 0.0001  
IgG anti-H3     0.48 
 LDLr(-/-) 0.32 0.09 0.001  
 High fat diet -0.36 0.1 0.001  
 Age 0.61 0.13 0.0001  
IgM anti-Cu-OxLDL      0.23 
 Age -0.43 0.1 0.0001  
IgG anti-Cu-OxLDL      0.46 
 Age 0.51 0.08 0.0001  
IgM anti-MDA-LDL      0.24 
 LDLr(-/-) 0.13 0.062 0.031  
 High fat diet -0.23 0.07 0.001  
 Age 0.34 0.08 0.0001  
IgG anti-MDA-LDL      0.26 
 Age 0.5 0.127 0.0001  
IgM anti-PC     No variable 
reached 
significant 
Table 5-3 Multivariate regression models for the level of antibodies in mouse 
serum.  
Strain, diet, and age are added into multiple regression models for each antibody. 
Only predictors that reached statistical significance are displayed. 
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5.3.3 Early dynamic of IgM anti-PC 
The decrease in IgM anti-PC with age was puzzling because there were opposite 
trends in LDL(-/-) mice fed with low fat diet (group L) and two other groups (Figure 
5-1-G). IgM anti-PC had an inverse correlation with age in group L while the 
correlations in groups B and H were both positive. I generated another cohort which 
included both LDL(-/-) and wild type on low fat diet. The sera were obtained from the 
same mice serially at the ages of 6, 8, 12, 16, and 20 weeks old via a saphenous vein. 
IgM anti-PC and the total IgM were measured as described above. 
 
The total IgM did not change with time in either LDLr(-/-) or wild type mice (Figure 
5-2, bottom). IgM anti-PC, however, began to drop from 8 weeks. The level 
decreased to a very low level at 16 weeks old. 
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(a)      (b) 
 
 
(c)      (d) 
 
 
Figure 5-2 Early dynamic of IgM anti-PC  
Mice were serially bled at 6, 8, 12, 16, and 20 weeks old. IgM anti-PC was steady in 
the wild type mice (a) but decreased dramatically in the LDL(-/-) mice (b). The total 
serum IgM were stable in both strains of mice (c and d). N=7 in each group. Values 
are expressed as mean ± SD 
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5.4 The correlation between anti-H3 and anti-OxLDL antibodies 
As the main purpose of this project was to generate and validate an anti-idiotype 
antibody as a surrogate antigen of OxLDL, I proceeded to examine the correlation 
between anti-H3 and other antibodies.  
5.4.1 IgG Anti-H3 
IgG anti H3 correlated positively and strongly with IgG anti-MDA-LDL (Spearman 
rho 0.72, p<0.0001) (Figure 5-3) and with IgG anti-Cu-OxLDL in mouse sera 
(Spearman rho 0.57, p<0.0001) (Figure 5-4).  
  
Figure 5-3 Relationship between IgG anti-H3 and anti-MDA-LDL in mice. 
 
Figure 5-4 Relationship between IgG anti-H3 and anti-Cu-OxLDL in mice.
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5.4.2 IgM Anti-H3 
IgM anti H3 correlated positively with IgM anti-MDA-LDL (Spearman rho 0.67, 
p<0.0001) (Figure 5-5) but negatively with IgM anti-Cu-OxLDL, (Spearman rho -
0.24, p=0.03) (Figure 5-6). IgM anti-H3 did not correlate with IgM anti-PC at all 
(Spearman rho 0.0.9, p=0.39) (Figure 5-7). 
 
Figure 5-5 Relationship between IgM anti-H3 and anti-MDA-LDL in mice. 
 
Figure 5-6 Relationship between IgM anti-H3 and anti-Cu-OxLDL in mice. 
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Figure 5-7 Relationship between IgM anti-H3 and anti-PC in mice. 
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5.4.3 Summary of correlations of antibodies in mouse sera 
To summarize, the level of anti-H3 in mouse serologic assays had a strong and 
positive correlation with MDA-LDL antibodies (both IgG and IgM). The level of anti-
H3 had a relatively weak positive correlation with IgG anti-Cu-OxLDL, but a weak 
negative one with IgM anti-Cu-OxLDL. There was no significant correlation between 
anti-H3 IgM and IgM anti-PC (Table 5-4 and Table 5-5). 
 
 H3 Cu-OxLDL MDA-LDL 
Cu-OxLDL 0.57 (p<0.0001) -- -- 
MDA-LDL 0.72 (p<0.0001) 0.73 (p<0.0001) -- 
Table 5-4 Correlation between IgG antibodies in mice sera 
Correlations, expressed as Spearman Rho (p value), are listed in this matrix, and, if 
statistically significant, shown in bold. IgG anti-PC was not detectable in mouse sera. 
 
 H3 Cu-OxLDL MDA-LDL PC 
Cu-OxLDL -0.24 (p=0.03) -- -- -- 
MDA-LDL 0.67 (p<0.0001) 0.05 (p=0.65) -- -- 
PC 0.09 (p=0.39) 0.4 (p<0.0001) 0.18 (p=0.09) -- 
Table 5-5 Correlation between IgM antibodies in mouse sera 
Correlations, expressed as Spearman rho (p value), are listed in this matrix, and, if 
statistically significant, shown in bold. 
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5.5 Summary and discussion 
The strong positive correlation between anti-H3 and anti-MDA-LDL antibodies is 
consistent with H3 being an effective surrogate antigen of MDA-LDL in serologic 
assays in the mice. The relationships between H3 and Cu-OxLDL antibodies, 
however, were weaker. This finding supports the idea that H3 has better mimicry to 
MDA-LDL than to Cu-OxLDL, perhaps because mAb LO1 shows stronger 
concentration related binding to MDA-LDL than Cu-OxLDL (Figure 3-9). Indeed, 
Cu-OxLDL is a very heterogeneous antigen, expressing many other epitopes apart 
from those formed by MDA-adduction and PC (Palinski, et al., 1990) (Horkko, et al., 
2000). Unexpectedly, the IgM anti-H3 did not correlate with IgM anti-PC although 
H3 had the PC-mimetic sequence on its CDR2/FR3(VH) (Table 4-4, page 87) and 
inhibited the binding of LO1 to PC-BSA. This may reflect the prediction that LO1 is a 
“group II” anti-PC antibody which requires a high concentration of immobilised PC-
BSA for detection of PC binding (see Chapter 3), whereas antibodies in serum that 
bind to PC-BSA at the coating concentration used in the assays (5 µg/ml) may be 
predominantly “group I” antibodies that do not bind to H3 (Brown, et al., 2000).  
 
Age is the most influential determinant of the level of antibodies against MDA-LDL, 
Cu-OxLDL, and H3 in mouse sera. The total cohort comprised 85 mice of wild type 
or LDLr(-/-) strains, fed with low or high fat diet. In the univariate analysis, age was 
the major determinant of antibodies (both IgG and IgM) against Cu-OxLDL, MDA-
LDL, and H3. The effect of strains is minimal, which agrees with Dimayuga’s 
finding, showing that both IgG and IgM anti-CuOxLDL or MDA-LDL increase with 
age (Dimayuga, et al., 2006). The multiple-variable regression models showed the 
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effect the complex interaction between strain, diet, and age had on antibodies. Age, 
however, remained the strongest independent predictor for all antibodies studied here 
except IgM anti-PC. 
 
The correlation between IgM anti-PC and age was complex but masked in the overall 
statistics. In the LDLr(-/-) mice on low fat diet, IgM anti-PC decreased with age. A 
subsequent separate cohort of mice that were serially bled produced a similar trend. 
This observation, however, contradicts with Dimayuga’s report which found an 
increase of IgM anti-PC with age in ApoE(-/-) mice fed with high fat diet (Dimayuga, 
et al., 2006). There are several possible explanations for this contradiction. First, mice 
fed with low fat diet might have different immune responses from those from mice 
fed with high fat diet, which leads to high metabolic stress. Second, the decline in 
IgM anti-PC might have been due to the maturation of anti-PC antibody response. 
Simple class switching from IgM anti-PC to IgG anti-PC is unlikely as we did not 
detect IgG anti-PC in the mouse serum using PC-BSA as antigen. However it is 
possible that specificity might have developed with affinity maturation in such a way 
that PC becomes only recognised in the context of a specific lipid or peptide carrier, 
as opposed to BSA (Brown, et al., 2000).  
 
Two further points need to be made in interpreting serum levels of autoantibodies. 
The first is that steady levels of serum do not necessarily reflect the rate of antibody 
turnover, and it is possible that both synthesis and consumption might be increased 
together in response to, for example, hypercholesterolaemia. The second point is that 
the data are limited to a single dilution for each assay, and it is possible that different 
results might have been obtained if antibody titration had been used as an end-point. 
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Thus optical density at optimal dilution is thought to favour the measurement of high 
affinity antibodies whereas titration may favour the measurement of quantity of 
antibodies of lower affinity (Lehtonen & Eerola, 1982). 
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CHAPTER 6 Results IV: antibodies reacting with OxLDL 
and H3 in human  
6.1 Chapter Introduction 
The use of H3 as a surrogate antigen in humans was tested with two sets of serum 
samples. The older group is coded as PARSEC, and the younger is coded as ICH in 
the following sections. 
 
The PARSEC study was designed to investigate the relationships between peripheral 
arterial disease and coronary disease in people of European and South Asian descent. 
This set of samples was collected by Professor Nish Chaturvedi’s group (Chaturvedi, 
et al., 2007). The ICH samples were collected by Professor Atul Singhal’s group for 
investigating coronary artery risk factors in adolescents (Halcox, et al., 2005; Singhal, 
et al., 2001). 
 
The first parameter I tested was age, which was the major determinant of the level of 
autoantibodies against OxLDL in the mouse studies described in CHAPTER 5. Next, 
the CAD-related traits were examined since the major purpose of this project was to 
develop and test a new serological measurement to predict CAD. Six parameters 
(CAD status, CAD duration, coronary CT score, LAD stenosis severity by 
angiography, carotid IMT, and femoral IMT) were correlated with levels of 
antibodies. Then the statistically significant correlations were examined in the model 
against traditional risk factors for multiple regression analysis. Thirdly, the effect of 
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ethnicity on these antibodies was measured. The PARSEC study was designed 
initially to detect the differences in the prevalence of peripheral arterial disease 
among people of different ethnicities who had a similar level of coronary disease and 
traditional risk factors (Chaturvedi, et al., 2007). Ethnicity, therefore, might have an 
important effect on these antibodies. Fourthly, since H3 appears to be a good mimic 
of OxLDL, whether H3 blocks the binding of human serum to Cu-OxLDL, MDA-
LDL, and PC-BSA was examined. 
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6.2 Material and methods 
6.2.1 Patient recruitment  
The PARSEC (Peripheral ARtery disease in South Asian and European men with 
Coronary artery disease) study enrolled 159 participants. All subjects were male and 
at least 45 years old. The study was restricted to men to avoid the confounding effect 
of gender. They were recruited from two sources: (1) Seventy nine healthy controls 
who had not been clinically diagnosed with CAD were drawn from a family practice 
in north-west London; (2) seventy nine CAD patients who had been diagnosed by 
coronary angiography were enrolled from a referral centre for the same family 
practice, namely the cardiology clinic at St Mary’s Hospital in London, UK. The 
ethnic distribution in both groups was balanced as shown below (Table 6-1). 
Peripheral venous blood was collected into siliconized Vacutainer tubes containing 
trisodium citrate (Becton Dickinson, Oxford, UK) by clear venepuncture. The sera 
were stored at -80°C until analysed. The average storage time of samples used in this 
project was 5 years. All participants had undergone computed tomography coronary 
artery calcification (CAC) scoring as described (Tillin, et al., 2007). Individuals were 
classified by Houndsfield Units (HU) into four categories of CAC (0–10 HU, 11–
100HU, 101–400 HU, >400 HU) as other researchers in the study of coronary CT had 
suggested (Vliegenthart, et al., 2005). The duration of IHD was expressed as the 
difference between the date of doctor diagnosis of CAD and the date of study visit. 
Men with coronary stents, atrial fibrillation, unstable angina, or other severe co-
morbidity were excluded. The study was approved by the ethics committee at St. 
Mary’s Hospital and all participants had given their informed consent.  
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Study subjects Healthy control With coronary artery disease 
European 41 42 
South Asian 43 41 
Table 6-1 The ethnic distribution within the CAD and control groups.  
 
The complete demographic, medical history, lifestyle, biochemistry, echography, 
coronary calcification data and the comparisons between the two ethnic groups have 
been published by Chaturvedi’s group (Chaturvedi, et al., 2007). 
 
The ICH cohort comprised 110 healthy (free from hypertension, hyperlipidemia, and 
diabetes mellitus) male adolescents aged 13-16 years. The initial purpose of this 
cohort was to find out the prevalence of risk factors of atherosclerosis in adolescents. 
Almost all individuals enrolled were Caucasian. Singhal’s group published the 
detailed demographic and metabolic characteristics of ICH cohort in 2001 (Halcox, et 
al., 2005; Singhal, et al., 2001). 
 
6.2.2 Measurement of antibodies 
Circulating antibodies against H3, Cu-OxLDL, MDA-LDL, and PC were quantified 
in sera by ELISA and detected at 450 nm as described in section 5.2.3 (page 95). All 
samples were measured in triplicate wells. The measurements from the wells coated 
with native LDL or control scFv were subtracted as background in anti-OxLDL and 
anti-H3 ELISAs respectively. The only major methodological differences from the 
ELISAs performed on mouse sera were the dilution of samples (see Table 6-2) and 
the use of biotionyted mouse anti-human IgG (Southern biotech, cat# 9040-08) or 
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IgM (Southern biotech, cat# 9022-08) secondary antibodies. All samples were 
measured in triplicate wells. Plate-to-plate variability was corrected by putting LO1 at 
1µg/ml (detected by anti-mouse conjugate) and several control samples on all plates 
to serve as references. Variability was less than 10% in all eight assays. 
Reproducibility of the assay was assessed by repeated measurements, and the 
coefficient of variation was determined to range from 6 to 15%. 
Serum dilution IgM IgG 
H3 100 100 
MDA-LDL 200 150 
Cu-OxLDL 50 100 
PC 200 100 
Table 6-2 Dilution of human sera 
 
6.2.3 Statistical analyses 
Values are expressed as mean ± standard deviation, medians (25th, 75th percentile) 
for skewed data, or a percentage (n). Mann-Whitney test was used to compare the 
levels of antibodies between two groups. Kruskal-Wallis test with Bonferroni 
correction was used to compare the levels of antibodies among three or more groups. 
Spearman’s rank correlation coefficient was used to estimate the association between 
different antibodies. A logistic regression model adjusted for traditional risk factors 
was applied to determine the association between antibodies and the development of 
CAD. Statistical significance was set at 0.05. The statistical software used were Prism 
4.0 (GraphPad, USA) or Stata 9.0 (Stata Corporation, USA). 
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6.3 Levels of anti-OxLDL antibody in human (PARSEC cohort) 
6.3.1 Baseline characteristics 
The baseline characteristics of healthy control and patients with CAD are shown in 
Table 6.3 for comparison and easy reference. All data were obtained from the 
PARSEC database provided by Professor Chaturved’s group (Chaturvedi, et al., 
2007). Patients with CAD were on average older than healthy controls (64 versus 60 
years old). The control group had higher diastolic blood pressure (84 versus 80 
mmHg), total cholesterol (4.7 versus 4.1 mmol/l), and LDL cholesterol (2.9 versus 2.2 
mmol/l). The CAD patients had better blood pressure and lipid profiles because most 
of them were on antihypertensive and lipid-lowering therapies. On the other hand, the 
disease groups had higher fasting glucose (5.5 versus 5.3 mmol/l) and HbA1c (6.4 
versus 5.9 %). The two groups had a similar profile on diabetes. Not surprisingly, 
patients with CAD were more likely to have been diagnosed with hypertension (Table 
6-3). 
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Variable Control CAD p 
N 81 78  
Age (years) 59.5±8 64±9 0.001 
Systolic BP (mmHg) 139±19.1 138±18.4 0.86 
Diastolic BP (mmHg) 84±9.6 80±6.9 0.004 
Heart rate (bpm) 64±11 62±9 0.33 
BMI (kg/m^2) 27±4 27.8±3.5 0.22 
Waist circumference (cm) 97±11 101±8 0.009 
Thigh circumference (cm) 51±8.4 51±5.9 0.88 
Fasting glucose (mmol/l) 5.3 (5, 6) 5.5 (5.1, 6.4) 0.036 
HbA1c (%) 5.9±0.75 6.35±1.12 0.019 
Total cholesterol (mmol/l) 4.7±0.8 4.1±0.9 <0.0001 
HDL cholesterol (mmol/l) 1.22±0.33 1.12±0.29 0.0516 
LDL cholesterol (mmol/l) 2.92±0.7 2.25±0.77 <0.0001 
Fasting triglyceride (mmol/l) 1.1 (0.9, 1.6) 1.3 (0.9, 1.9) 0.1 
Fasting insulin (pmol/l) 44 (28, 71) 57 (34, 104) 0.035 
CRP (mg/L) 1.4 (0.6, 4.3) 1.6 (0.7, 3.3) 0.58 
Known diabetes % (n) 17.5 (14) 25 (19) 0.52 
Known hypertension % (n) 39.2 (29) 64.5 (49) <0.0001 
Table 6-3 Baseline characteristics of PARSEC cohort. 
The data were divided by disease status. Variables reaching statistical significance are 
shown in bold. Values are expressed as means ± S.D., or median (25th, 75th 
percentile), or % (sample size).
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6.3.2 Age and level of antibodies 
The PARSEC cohort included only men older than 45 years old. Antibodies against 
H3, Cu-OxLDL, MDA-LDL, and PC did not change with age within the time frame 
of the samples (Figure 6-1, page 122). Further analyses of control healthy or CAD 
patients revealed no significant trend in all 8 assays for the subjects at different ages.  
 
To extend the range of age in this study, a younger cohort ICH samples (110 healthy 
boys aged from 13-16 years old) was compared with 40 randomly selected Caucasian 
PARSEC control subjects. The selection of these subjects therefore excluded any 
possible effects of sex and ethnicity. The young controls had a higher level of IgM 
against H3, MDA-LDL, and PC. Age had no effect on the levels of IgG for all three 
antigens (Figure 6-2).  
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IgM anti-H3     IgG anti-H3 
 
IgM anti-Cu-OxLDL     IgG anti-Cu-OxLDL  
 
IgM anti-MDA-LDL     IgG anti-MDA-LDL  
 
IgM anti-PC     IgG anti-PC 
 
Figure 6-1 Age and antibodies in PARSEC cohort  
No obvious correlation between the antibodies examined and age. Unit of Y-axis: corrected OD450. 
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Figure 6-2 Level of antibodies of adolescent and old Caucasian males without 
CAD 
The ICH (n=110) cohort had higher anti-PC, anti-MDA-LDL and anti-H3 IgM than 
the PARSEC group (n=40). The level of IgG antibodies in the two groups was 
similar. The values are presented as median and quartiles. Mann-Whitney test was 
used to compare the levels between the groups.
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6.3.3 CAD-related traits 
6.3.3.1 CAD status 
CAD status was defined as 50% or more stenosis found by coronary angiography. 
Figure 6-3 shows the comparison of the eight assays. The CAD group had a higher 
level of IgM anti-Cu-OxLDL (p=0.06). There was no significant difference between 
the healthy control and CAD groups for all the other antibodies examined. 
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IgM anti-H3  (p=0.87)   IgG anti-H3 (p=0.64) 
 
IgM anti-Cu-OxLDL (p=0.06)  IgG anti-Cu-OxLDL (p=0.96) 
 
IgM anti-MDA-LDL (p=0.17)  IgG anti-MDA-LDL (p=0.61) 
 
 
IgM anti-PC (p=0.29)    IgG anti-PC (p=0.08) 
 
Figure 6-3 Antibodies of healthy control and CAD  
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(Continued) The graphs show the levels of antibodies of the control (Left bar, n=78) 
and the disease (right bar, n=78) groups. The levels of antibodies are arbitrary units. 
The difference between groups was determined by Mann-Whitney test. The values are 
presented as median and quartiles. There was no difference for all antibodies between 
the control and disease groups
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6.3.3.2 Duration of CAD  
Within the disease group, the duration of doctor-diagnosed CAD was correlated with 
the level of antibodies in diseased group of PARSEC cohort. (Figure 6-4) The 
duration of CAD had no correlation with the level of antibodies. 
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IgM anti-H3  (rho=0.11, p=0.32)  IgG anti-H3 (rho=0.06, p=0.58) 
 
IgM anti-Cu-OxLDL (rho=-0.14, p=0.22) IgG anti-Cu-OxLDL (rho=-0.004, p=0.97) 
 
IgM anti-MDA-LDL  (rho=-0.12, p=0.27) IgG anti-MDA-LDL (rho=0.13, p=0.23) 
 
IgM anti-PC (rho=0.15, p=0.18)   IgG anti-PC (rho=0.08, p=0.47) 
 
Figure 6-4 The correlation of CAD duration and antibodies 
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(Continued) The charts on the previous page show the correlations between antibodies 
and durations in years of doctor diagnosed ischemic heart disease. The levels of 
antibodies are arbitrary units. Correlation was evaluated by Spearman's rank 
correlation (rho). There was no correlation between the level of antibodies and the 
duration of disease. 
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6.3.3.3 Coronary CT calcification score (CAC) 
The individuals in the PARSEC cohort were classified by Hounsfield Units (HU) into 
four categories of CAC (0–10 HU, 11–100HU, 101–400 HU, >400 HU). The 
difference among the groups was compared by Kruskal-Wallis rank test. There was 
no significant difference between the low and high CAC categories (Figure 6-5). 
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IgM anti-H3  (p=0.91)   IgG anti-H3 (p=0.74) 
 
IgM anti-Cu-OxLDL (p=0.89)  IgG anti-Cu-OxLDL (p=0.69) 
 
IgM anti-MDA-LDL  (p=0.81)  IgG anti-MDA-LDL (p=0.66) 
 
IgM anti-PC (p=0.78)    IgG anti-PC (p=0.51) 
 
Figure 6-5 Coronary CT score and antibodies in PARSEC  
(Continued) The charts on the previous page show no correlation between antibodies 
and coronary calcification scores. The levels of antibodies are arbitrary units. The 
 132 
patients’ CAC scores were classified into four groups by Hounsfield Units. The 
values are presented as median and quartiles. 
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6.3.3.4 Severity of LAD stenosis  
All patients in the CAD group underwent a quantitative diagnostic coronary 
angiography. Using stenosis at left descending artery (LAD) >50% as the cut off point 
(Wei, et al., 2001), the group with severe stenosis had lower anti-H3 IgG (p=0.037). 
Otherwise, there was no significant difference between the groups with mild and 
severe stenosis for all the other antibodies (Figure 6-6). 
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IgM anti-H3 (p= 0.53)   IgG anti-H3,  (p=0.037) 
 
IgM anti-Cu-OxLDL (p=0.8) IgG anti-Cu-OxLDL (p=0.75) 
 
IgM anti-MDA-LDL  (p=0.09)  IgG anti-MDA-LDL (p=0.7) 
 
IgM anti-PC (p=0.4)    IgG anti-PC (p=0.25) 
 
Figure 6-6 Antibodies in group with mild and severe stenosis  
These charts show the comparisons of antibodies between patients with mild LAD 
stenosis (left bars, stenosis area < 50%) and severe stenosis (right bars, stenosis area> 
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50%). The levels of antibodies are arbitrary units. Individuals with severe stenosis had 
lower levels of anti-H3 IgG. The difference was tested by Mann-Whitney test. The 
values are presented as median and quartiles.
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6.3.3.5 Intima-media thickness (IMT) 
IMT is a commonly used indicator for atherosclerosis. All participants in the 
PARSEC study had their carotid and femoral IMT measured. 
6.3.3.5.1 Carotid IMT 
Carotid IMT is a commonly used index of atherosclerosis and has been used in many 
studies of anti-OxLDL antibodies as an indicator of atherosclerosis (Polak, 2005). I 
tested the cohort’s carotid IMTs against the eight antibodies, and I found that only 
IgG anti-MDA-LDL had a statistically significant positive correlation with carotid 
IMT. This correlation, however, is rather weak (Spearman rho = 0.25) (Table 6-4). 
 
Antibodies Spearman rho p value 
IgM anti-H3 -0.12 0.17 
IgG anti-H3 0.06 0.43 
IgM anti-Cu-OxLDL  0.003 0.96 
IgG anti-Cu-OxLDL  0.15 0.07 
IgM anti-MDA-LDL  0.03 0.67 
IgG anti-MDA-LDL  0.25 0.0021 
IgM anti-PC -0.01 0.9 
IgG anti-PC -0.03 0.71 
Table 6-4 Correlation between antibodies and carotid IMT 
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6.3.3.5.2 Femoral IMT 
Femoral IMT sometimes provides additional but different information about 
atherosclerosis than that provided by carotid IMT (Tillin, et al., 2007). However, my 
study found that femoral IMT did not correlate with any of the autoantibodies studied 
(Table 6-5). 
 
Antibodies Spearman rho p value 
IgM anti-H3 -0.07 0.4 
IgG anti-H3 0.01 0.85 
IgM anti-Cu-OxLDL  0.004 0.96 
IgG anti-Cu-OxLDL  0.08 0.3 
IgM anti-MDA-LDL  0.03 0.65 
IgG anti-MDA-LDL  0.12 0.17 
IgM anti-PC -0.02 0.77 
IgG anti-PC -0.03 0.68 
Table 6-5 Correlation between antibodies and femoral IMT 
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6.3.3.6 Traditional CAD risk factors  
In the analysis of the 6 different end points vs. the 8 antibodies, only 3 pairs reached 
statistical significance, and they were (1) IgM anti-Cu-OxLDL was borderline higher 
in the CAD group, (2) IgG anti-MDA-LDL correlated positively with carotid IMT, 
and (3) IgG anti-H3 was lower in the patients with severe stenosis than in the patients 
with mild stenosis. A further analysis was performed to examine whether they are 
independent in the context of traditional risk factors, including age, smoke, diabetes, 
hypertension, and total cholesterol (de Lorgeril, et al., 1999). 
 
6.3.3.6.1 IgM anti-Cu-OxLDL vs. CAD status  
IgM anti-Cu-OxLDL was a statistically independent predictor in the models which 
included traditional factors (Table 6-6). A higher level of this antibody indicated a 
mildly increased risk of CAD although the standard error was high. Old age and 
diagnosed hypertension are also independent and positive predictors. Surprisingly, the 
CAD group had lower levels of total cholesterol, which might be attributable to the 
fact that those patients were taking lipid-lowering drugs.  
Factor Odds ratio Std. Error p 95% Confidence interval 
IgM Anti Cu-OxLDL 13.73 12.85 0.05 1.03 201.9 
Age 1.05 0.02 0.03 1.005 1.106 
Total cholesterol 0.51 0.107 0.001 0.34 0.77 
Diabetes 1.09 0.51 0.85 0.43 2.77 
Hypertension 2.67 1.10 0.01 1.27 5.6 
Smoke 1.04 0.42 0.92 0.46 2.33 
Table 6-6 Independent predictors of CAD status.  
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6.3.3.6.2 IgG anti-MDA-LDL vs. carotid IMT 
IgG anti-MDA-LDL was not an independent predictor of carotid IMT although there 
was a positive correlation in the univariate analysis. The only significant factor in this 
model was age, which has a positive association with carotid IMT (Table 6-7). 
Factor Coefficient Std. Error p 95% Confidence interval 
IgG anti-MDA-LDL 0.03 0.06 0.63 -0.1 0.17 
Age 0.01 0.002 0.0001 0.005 0.015 
Total cholesterol 0.01 0.02 0.42 -0.02 0.05 
Diabetes 0.02 0.04 0.63 -0.07 0.12 
Hypertension 0.05 0.04 0.15 -0.02 0.17 
Smoke 0.056 0.04 0.19 -0.28 0.47 
Table 6-7 Determinant of carotid IMT  
 
6.3.3.6.3 Anti-H3 IgG vs. extent of LAD stenosis 
Only IgG anti-H3 reached statistical significance in this model, in which 50% stenosis 
of LAD served as the cut-off point. Higher anti-H3 IgG predicted a lower risk of 
severe LAD stenosis (lumen area occluded >50%) (Table 6-8). 
Factor Odds ratio Std. Error p 95% Confidence interval 
Anti-H3 IgG 0.01 0.02 0.002 0.001 0.46 
Age 1.01 0.04 0.62 0.94 1.1 
Total cholesterol 2 0.8 0.08 0.91 4.4 
Diabetes 2.7 2.2 0.2 0.58 13.1 
Hypertension 1.46 1.03 0.53 0.36 5.86 
Smoke 2.96 2.4 0.18 0.59 14.69 
Table 6-8 Independent predictors of the extent of LAD stenosis 
 140 
 
6.3.3.7 Brief summary of CAD-related traits 
To summarize, eight antibody assays were tested against six available and commonly 
used CAD-related traits for correlation. The results obtained from this matrix were 
complex. Three of these traits, the duration of CAD, coronary calcification score by 
CT, and femoral IMT, did not correlate with any antibodies tested in this project. 
Patients with CAD had higher levels of IgM anti-Cu-OxLDL than healthy control did; 
CAD patients with milder LAD stenosis had higher IgG anti-H3; and carotid IMT had 
a positive correlation with IgG anti-MDA-LDL. One must be aware that in an array of 
48 correlations, two or three false positive statitics might be found if type 2 error is 
5%. 
 
There are no consistent results obtained from this matrix, however, we can propose 
some interesting possibilities. For example, the “positive” linkages between 
antibodies and two atherosclerosis-related traits suggest that IgM anti-Cu-OxLDL and 
IgG anti-MDA-LDL are “atherogenic”. Conversely, its “negative” linkage might hint 
that anti-H3-IgG is “atheroprotective”. 
 
From the models of multivariate regression with traditional risk factors, my study 
concludes that a higher level of IgM anti-Cu-OxLDL predicts CAD and a lower level 
of IgG anti-H3 predicts more severe stenosis of LAD in the PARSEC cohort. 
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6.3.4 Ethnicity 
The PARSEC study concluded that, with equivalent levels of coronary disease, Indian 
Asians have significantly lower chances of peripheral arterial disease than do 
European men (Chaturvedi, et al., 2007). Miller and colleagues also reported an 
ethnic variation in the levels of anti-OxLDL IgG (Miller, et al., 2009). The titre of 
anti-OxLDL IgG in people of African or South Asian origin was higher than that in 
whites. Therefore, we screened eight antibody assays for any differences between 
South Asian and European subjects, and we found that South Asians had higher anti-
H3 IgG while Europeans had higher IgM anti-Cu-OxLDL and IgM anti-MDA-LDL.  
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IgM anti-H3 (p=0.65)    IgG anti-H3, p=0.024  (European < Asian) 
  
IgM anti-Cu-OxLDL, p=0.007 (European > Asian)  IgG anti-Cu-OxLDL (p=0.33) 
 
IgM anti-MDA-LDL, p=0.004 (European > Asian)  IgG anti-MDA-LDL (p=0.74) 
 
IgM anti-PC (p=0.93)    IgG anti-PC (p=0.46) 
 
Figure 6-7 Antibodies of different ethnic groups 
The graphs show antibodies comparisons between the European (left bars, n=79) and 
South Asian (right bars, n=80) groups. The South Asian group had higher IgG anti-
H3, but lower IgM anti-Cu-OxLDL and IgM anti-MDA-LDL. The levels of 
antibodies are arbitrary units. The difference was tested by Mann-Whitney test. The 
values are presented as median and quartiles.
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6.4 The correlation between anti-H3 and anti-OxLDL antibodies 
The correlation between the level of antibodies against H3 and the levels of antibodies 
against MDA-LDL, Cu-OxLDL, and PC is obviously important in validating H3 as a 
surrogate antigen. In PARSEC samples, anti H3 IgG correlated strongly with both 
anti-OxLDL and anti-MDA-LDL antibodies, but not with anti-PC antibodies in serum 
(Table 6-9 and Table 6-10). 
 
Antibodies Spearman rho p value 
IgG anti-MDA-LDL 0.47 P<0.0001 
IgG anti-Cu-OxLDL 0.41 P<0.0001 
IgG anti-PC 0.09 0.25 
Table 6-9 Correlation between IgG anti-H3 and other IgG antibodies in 
PARSEC 
 
Antibodies Spearman rho p value 
IgM anti-MDA-LDL 0.45 P<0.0001 
IgM anti-Cu-OxLDL 0.49 P<0.0001 
IgM anti-PC 0.31 0.06 
Table 6-10 Correlation between IgM anti-H3 and other IgM antibodies in 
PARSEC 
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6.5 H3 does not inhibit the binding of human serum to OxLDL 
Since H3 may mimic OxLDL structurally, whether H3 inhibits the binding of human 
serum to Cu-OxLDL, MDA-LDL, and PC-BSA was also examined. Five samples of 
PARSEC with high antibody titres were selected randomly for each competition 
ELISA and none of these were inhibited by H3 (Figure 6-8). 
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Figure 6-8 H3 does not inhibit the binding of human serum to OxLDL 
The reactivity of human serum to Cu-OxLDL, MDA-LDL, or PC-BSA was not 
blocked by H3 or control scFv. The values are expressed as mean + SEM. 
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6.6 Summary and discussion 
Antibodies against H3 correlated with antibodies against MDA-LDL and Cu-OxLDL 
in the PARSEC cohort. The positive association of anti-H3 and anti-MDA-LDL 
antibodies is similar to what was found in mouse sera (CHAPTER 5). This correlation 
provides further support for H3 acting a surrogate antigen for MDA-LDL in serologic 
assays. However the failure of H3 to inhibit human serum antibodies to the MDA-
LDL and to the other two antigens underscores the point that the respective antibody 
populations are clearly not identical (Figure 6-8). Generally, the antibodies tested in 
this study do not have significant correlations with atherosclerosis. However, they 
might have prognostic implications in specific subgroups. Age and ethnicity also have 
some effect on anti-MDA-LDL and anti-H3 IgM antibodies. 
 
6.6.1 Markers for severity of coronary stenosis 
The level of IgM anti-Cu-OxLDL was marginally higher in patients with CAD than in 
healthy controls. This observation agrees with Maggi’s findings that both IgM and 
IgG against MDA-LDL were higher in patients with severe carotid atherosclerosis 
who had undergone carotid artery endarterectomy than in matched control (Maggi, et 
al., 1994). Another similar correlation was reported by Meraviglia et al, who had 
demonstrated a positive correlation between IgM Cu-OxLDL and carotid IMT 
progression in 52 patients with severe atherosclerosis (Meraviglia, et al., 2002). 
However, there have been some contrary observations that IgM Cu-OxLDL correlated 
negatively with atherosclerosis. IgM anti-Cu-OxLDL related inversely with carotid 
IMT in patients with hypercholesterolemia (Hulthe, et al., 1998) and in health 
population (Hulthe, Bokemark, et al., 2001). A much larger study with 1022 volunteer 
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individuals also produced an identical result (Karvonen, et al., 2003). Tsimikas et al, 
examined IgM against Cu-OxLDL in 504 patients who had undergone coronary 
angiography and found no correlation between antibody and CAD (Tsimikas, et al., 
2007). These contradictory observations might be attributable to the different cohorts, 
endpoints, study designs, and more importantly, use of non-standardised assays, 
which this study attempts to address and resolve.  
 
Patients with milder LAD stenosis had higher anti-H3 IgG levels. Most interestingly, 
this difference remained in the multivariate analysis in the model which included 
traditional CAD risk factors. IgG against H3 actually was the sole independent factor 
in this model. These findings must be interpreted with caution because all subjects in 
this group had been treated intensively with statin and other medication. Despite that, 
IgG against H3 is a LDL-related marker showing an inverse correlation with the 
severity of coronary stenosis. Similarly Sjogren has reported that antibodies against 
selected short peptides of apoB-100 (p210) correlate inversely with the degree of 
coronary stenosis as measured by angiography (Sjogren, et al., 2008). The duration of 
disease has no effect on any antibodies measured in this study. However, the duration 
of disease in the PARSEC cohort was a rough estimation obtained from a 
questionnaire, and an effect might have been masked. 
 
The difference in IgG anti-H3 between the ethnic groups (Asian subjects having a 
higher level) is not attributable to LAD stenosis. The two ethnic populations had 
similar extent of LAD stenosis (p=0.16, Mann-Whitney test). This might be 
considered as additional indirect evidence that supports the notion that IgG anti-H3 is 
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an independent risk factor for LAD stenosis because ethnicity was not added in the 
multivariable analysis for traditional risk factors.  
 
This study has not been able to demonstrate a correlation between the other antibodies 
against the modified LDL preparations that were examined and CAD related 
endpoints—a fact consistent with the findings of many previous studies in this field. 
The largest and the longest lasting of these studies was carried out by Wilson et al, 
who had followed more than 2,600 people for eight years in the Framingham 
Offspring Study and found no correlation between MDA-LDL antibodies and CAD 
events (Wilson, et al., 2006).  
 
6.6.2 Effect of age on IgM anti-MDA-LDL and anti-PC in a healthy population 
In the healthy male population of this study, the younger subjects from ICH have 
higher levels of IgM anti-MDA-LDL, IgM anti-PC, and IgM anti-H3 than the older 
ones from PARSEC. The levels of IgG anti-MDA-LDL, PC, and H3 were the same in 
the two groups of subjects. In the PARSEC cohort, however, age had no correlation 
with any of the eight antibodies. Only few previous studies reported diverse data on 
the effect of age on OxLDL related antibodies. Tinahones et al. argued that the 
younger population (16-35 years old) had higher levels of IgG anti-MDA-LDL than 
people older than 36 years (Tinahones, et al., 2005). Wilson et al. also reported a 
positive correlation between age and IgG against MDA-LDL in a healthy population 
of subjects between the ages of 20 and 70 years old (Wilson, et al., 2006). Both 
studies focused on the general population and had decent sample sizes (n=1354 in 
Tinahones’ and 2619 in Wilson’s). This contradiction in the correlation was further 
complicated by two smaller studies: (1) young healthy adults (aged 17-25, n=96) had 
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higher IgG anti-Cu-OxLDL than middle aged healthy adults (aged 45-65, n=147) 
(Karabinos & Koulouris, 2007) and (2) older men had higher anti-OxLDL IgG than 
younger ones in an overweight male population (n=109 in total) (Karolkiewicz, et al., 
2006). Fraley et al. reported the largest series (n=2342) of patients with acute 
coronary syndrome and found younger patients (65 years old or younger) had higher 
levels of anti-MDA-IgM than older ones (Fraley, et al., 2009). Our result is in line 
with Tinahones’s finding which showed that young people have higher IgM anti-
MDA-LDL in a healthy population, but we have been unable to demonstrate the 
negative correlation between age and IgG anti-MDA-LDL that was shown in Fraley’s 
study. 
 
The correlation between anti-OxLDL antibodies levels and age in human is reversed 
in mice. This discrepancy may be due to the numerous differences between the study 
models for mouse atherosclerosis and those for human atherosclerosis. A highly 
simplified way to put it is that LDL(-/-) mice only reflects an aspect of human 
atherosclerosis, and mice do not express the same atherosclerosis phenotype (Cullen, 
et al., 2003). More importantly, the immune system of mice is distinct from that of 
human. Finally, it bears repeating that we used human LDL as antigen in this study, 
and H3 is an anti-idiotype against a mAb raised against human OxLDL. It is possible 
that different results might have been obtained with mouse sera if we had used mouse 
OxLDL.  
 
6.6.3 Effect of ethnicity on the antibodies tested 
Different ethnic groups had different levels of antibodies to oxidized LDL. In the 
PARSEC cohort, South Asians had higher anti-H3 IgG, lower Cu OxLDL IgM and 
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lower MDA-LDL IgM. Miller et al reported that South Asians had higher anti-
OxLDL IgG than Caucasian (Miller, et al., 2009). My study has been unable to 
replicate their observations. However, I did find that South Asians had lower anti-cu-
OxLDL and IgM anti-MDA-LDL than Caucasian. The difference in the levels of 
antibodies between South Asians and Caucasians may be explained by numerous 
factors such as genetic variation, nutrition or diet. 
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CHAPTER 7 Discussion  
This study attempts to address two main questions. First, whether an anti-id scFv 
protein can serve as a surrogate antigen to take the place of OxLDL; secondly, 
whether such a protein is a good predictor of atherosclerosis.  
 
With respect to the first question, this study has found that an anti-idiotypic scFv (H3) 
has dual structural similarities to the protein and the lipid components of OxLDL 
(Figure 4-7, page 89). Antibodies against H3 correlate strongly with antibodies to 
MDA-LDL, and so H3 may serve as a surrogate antigen for MDA-LDL in serologic 
assays in both mice and humans. Antibodies against H3 do not correlate so well with 
Cu-OxLDL and do not associate with PC at all. 
 
Regarding the second question, this study has found that antibodies to various OxLDL 
preparations do not significantly correlate with atherosclerosis in the PARSEC study, 
with the exception of IgM anti-Cu-OxLDL, which correlated positively but weakly 
with CAD. All the other assays used in this study were also used by other researchers 
in numerous previous studies, which have failed to detect a statistically significant 
difference between disease and control groups (Table 2-4, page 38). Therefore these 
previous studies suggested that anti-OxLDL antibodies might not be reliable markers 
for atherosclerosis in the general population. However my study has achieved a novel 
and potentially important observation that the molecularly-definable and reproducible 
H3 scFv is a better predictor of the extent of LAD stenosis in the PARSEC cohort 
than the traditional risk factors and antibodies to OxLDL antigens are. 
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7.1 scFv H3 acts as a surrogate antigen for oxidised LDL and a potential 
marker for the extent of CAD 
H3 appears to be a good surrogate for MDA-LDL. The main evidence supporting this 
argument is fourfold. First, the ability of H3 to block the binding of the mAb LO1 to 
MDA-LDL. Secondly, the close correlation between anti-H3 ELISA data and anti-
MDA-LDL ELISA data in both mouse and human sera. Thirdly, the considerable 
similarities between H3's CDR2 (VH) and apoB and a PC mimetic peptide. Finally, 
the structural similarity between CDR2 (VL) of H3 and P102, a short fragment of 
apoB-100 which was related to antibody responses in atherosclerosis that Nilsson’s 
group reported (Fredrikson, et al., 2003). Like the shorter peptides mentioned above, 
scFv proteins have several advantages over ordinary OxLDL as antigens. scFv has a 
well-characterised structure, biochemistry, and physical stability. By contrast, OxLDL 
has unique and non-predictable properties in each individual preparation. This thesis 
suggests that an scFv anti-id, when used as an antigen, can allow standardization and 
quality control in serological assays involving complex antigens. 
 
We found that patients with more severe coronary stenosis had lower IgG anti-H3. 
This finding is in line with observations in previous studies of the atheroprotective 
effects of certain antibodies against OxLDL or MDA-LDL (Table 2-2, page 31). 
Sjogren reported that antibodies against selected short peptides of apoB-100 correlate 
inversely with the degree of coronary stenosis as measured by angiography. 
Independently, higher IgG anti-native P210 also predicts a lower risk of myocardial 
infarction (Sjogren, et al., 2008). With these two pieces of independent evidence in 
conjunction with the observation in this project, I suggest that immune responses 
 153 
against specific epitopes of apoB may be playing a role in protecting patients from 
coronary artery disease. 
 
7.2 Role of other anti-OxLDL antibodies as independent risk factors for 
the extent of atherosclerosis 
This study tested six ordinary oxidized LDL assays (IgM or IgG anti-Cu-OxLDL, 
MDA-LLD, and PC) in a broad range of CAD-related indices, including clinical, 
echographic, angiographic and CT parameters, and it found only one correlation. In 
the univariate analysis, a positive relationship between carotid IMT and IgG MDA-
LDL has been established. However, this project has not been able to establish the 
other anti-OxLDL antibodies examined as independent risk factors for CAD in the 
PARSEC cohort. This general lack of correlation is consistent with the findings of 
many previous studies, which showed that IgG and IgM autoantibodies to OxLDL did 
not correlate with the atherosclerosis-related traits as listed in Table 2-4 (page 38).  
 
These rather negative results underscore our initial assertion that the exact role that 
OxLDL antibodies play in atherosclerosis is subtle and may not be decipherable by 
using whole OxLDL particle as antigen because of their inherent complexity and 
heterogeneity. Adding this to differences in assay procedures, varying endpoints, and 
diverse study designs only makes the epidemiologic study of OxLDL antibodies more 
difficult. This study, like any clinical correlative study, cannot answer the big 
question of whether OxLDL antibodies are atherogenic or atheroprotective. However, 
my study shows that scFv H3, as a proof of concept, can be a defined and functional 
epitope that may detect a subset of anti-OxLDL antibodies. This study offers, via 
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studying scFv H3 as an OxLDL surrogate, a novel approach to shed light on the 
mystery of OxLDL antibodies and atherosclerosis. 
 
Beyond the debate over whether the role of OxLDL antibodies play in atherosclerosis 
is atherogenic or atheroprotective, one should always bear in mind that probably 
OxLDL antibodies are epiphenomena of the original atherogenic OxLDL (Freire de 
Carvalho, et al., 2007). The level of circulating OxLDL antibodies may depend 
largely on the amount and the degree of modification of LDL, the kinetics of antibody 
turnover, and the immune reactivity of the subjects. Therefore, it is essential to take a 
broader approach to decipher the potential effects of modified LDL antibodies. 
 
7.3 Limitations and advantages of this project 
7.3.1 Samples might not represent the whole 
Only one monoclonal antibody against OxLDL, LO1, was used for selecting anti-id, 
and only one scFv, H3, was used for further characterization. A given monoclonal 
antibody, LO1 in this study, is unlikely to represent the whole spectrum of anti-
OxLDL antibodies in serum. Similarly, a given anti-id, H3 in this project, cannot 
mimic all epitopes expressed on OxLDL.  
 
Another similar limitation is that OxLDL is just one of many potential antigens that 
may be related to atherosclerosis. Numerous other antigens such as HSP (Wick, et al., 
2004) and β2 glycoprotein 1 (Matsuura, et al., 2008) have been reported to be related 
to atherosclerosis. Even considering only LDL modifications, copper oxidation is 
merely one of many different types of LDL modifications. Copper oxidization of LDL 
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is highly unlikely to be the dominant pathway in vivo. Some researchers have 
suggested that enzymatic modifications, e.g., 12/15 lipoxygenase and 
myeloperoxidase, might have a more physiologic role in atherogenesis (Tsimikas, 
2006b).  
 
7.3.2 The limitation of the studied cohorts 
The samples used in this study were obtained from two different studies, and 
therefore a direct comparison might not be possible. The storage conditions of the two 
source studies were different which might have resulted in unknown biases 
notwithstanding the fact that immunoglobulin is commonly considered a stable 
protein in various environments and conditions. Both of these source cohorts have 
relatively small sample sizes (n = 159 in PARSEC, n=250 in ICH), which might be 
insufficient for the detection of subtle differences of antibodies against autoantigens. 
The analyses were retrospective and cross-sectional, so the findings should be 
interpreted with care until confirmed in a prospective study. More importantly, the 
PARSEC cohort was designed initially for the comparison of peripheral the arterial 
disease between different ethnic groups, which might not have been the best cohort 
for evaluating a novel biomarker like H3. Furthermore, two more factors, namely 
confounding diseases (e.g. diabetes) and medications (e.g. statins), would have made 
the interpretation of the results more difficult. While diabetes and statins have been 
reported as capable of affecting the level of anti-Cu-OxLDL antibodies (Festa, et al., 
1998) (Fraley, et al., 2009), these two factors were not independent factors for any of 
the antibodies examined in PARSEC. 
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7.3.3 Other technical considerations 
One of the technical considerations in this project is that only one dilution for each 
serum was used in the ELISAs, instead of serially diluting each serum in each ELISA. 
The optimal dilution ratio in this study was determined preliminarily by the titration 
of several randomly selected samples. The dilution giving the maximal ratio of 
signal/background was then used for all samples, and the results were expressed as 
standardised optical densities. This approach, however, might sometimes 
underestimate the abundance of low affinity antibodies in serum (Lehtonen, et al., 
1982). Nevertheless, the fixed dilutions were chosen in this study because the signal 
titrated well in all preliminary ELISAs, and it was not practicable to apply multiple 
dilutions on a large scale.  
 
7.3.4 Strengths of this study 
Despite these limitations, our method has several strengths over those previously used 
to study the humoral response to OxLDL. The first advantage is that the structure of 
scFv protein is definable and reproducible anywhere, which makes a standardized and 
comparable assay possible. The next strength is the comprehensiveness of the phage 
display platform. Unlike approaches that required MDA modified short peptides of 
fragmented apoB100 or oxidized phospholipid, our approach did not limit the scope 
to the apoB100 part of LDL, and it allowed for a broader range of potential epitopes, 
including lipids. The possible dual mimic sequence of apoB and PC on CDR2 (VH) 
supports this theory. 
 
The PARSEC cohort offers one primary advantages. The disease status has been 
confirmed by coronary angiography, a reliable tool for detecting advanced CAD. 
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What is more, the samples obtained from adolescent by ICH were extremely precious 
and difficult to collect. 
 
7.4 Future investigations 
Future work in the study of OxLDL may be focused on the further characterisation of 
LO1 and H3, the expansion of arrays of monoclonal antibodies and anti-ids, and 
ultimately finding a better biomarker for atherosclerosis.  
 
7.4.1 Further characterisation of LO1 and H3 
The reactivity of LO1 to mouse LDL and OxLDL, to atherosclerotic tissue, and to 
OxLDL in serum needs to be further examined. Since some anti-OxLDL antibodies 
bind to apoptotic cells (M. K. Chang, et al., 1999; Chou, et al., 2009), it will also be 
worth looking into see whether mAb LO1 binds to apoptotic cell membranes. 
However the resemblance of the H3 CDRs to apoB predicts that the answer will be 
negative.  
 
Further characterisation of H3 and analyses of the structural basis of H3-LO1 
interactions (i.e., immuno EM, co-crystallisation) are essential to the further 
understanding of H3. As mentioned above, the affinity isolation of antibodies 
recognised by H3 may demonstrate that antibodies reacts with OxLDL and that this 
reactivity can be inhibited by mAb LO1. The framework of H3 should not be 
antigenic in humans as it was derived from human immunoglobulin variable gene 
segments. The most likely key components of H3 for binding antibodies are therefore 
the CDRs (see Table 4-4, page 87 and Figure 4-7, page 89). Domain or the CDR 
swaps between H3 and a negative control scFv that does not bind to mAb LO1 should 
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determine exactly where the functional binding sites are located. This might lead on 
to in vitro “affinity maturation” by synthesizing and engineering the binding site(s) to 
maximize the mimicry of OxLDL either structurally or functionally. A modified 
version of H3 could then be the basis for numerous potential applications such as a 
“cleaner” surrogate of OxLDL and a potential vaccine to interfere with atherosclerosis 
pathogenesis (Caligiuri, et al., 2007). Using H3 as flow cytometry reagent may allow 
an analysis of the population of B cells making H3 antibodies, in a manner previously 
published by Diamond et al using an anti-id to an anti-DNA antibody (Newman, et al., 
2003). The immunogenicity of H3 (or its key CDR) could be tested by measuring the 
levels of antibodies against OxLDL or MDA-LDL after the immunisation of the mice. 
Finally, whether such immunisation has any effect on atherosclerosis in a LDL(-/-) 
model would be an acid test for this kind of vaccination experiment. 
 
7.4.2 More diverse reagents 
As pointed out earlier, a weakness of this study is that the number of idiotypic and 
anti-id antibodies tested was limited. Literally both LO1 and H3 are obtained by 
screening, and every screening process could result in different clones. Theoretically 
the more clones one screens, the better the chances that one can get a new marker to 
predict atherosclerosis. More monoclonal anti-OxLDL antibodies could be cloned by 
new high-throughput screening devices such as micro-engraving (Ogunniyi, et al., 
2009). Further experiments with surface plasmon resonance (Biacore) would facilitate 
the screening of scFv by measuring the affinity of multiple clones rapidly. 
 
More OxLDL-related antigens would allow researchers to approach atherogenesis 
with more precision. Neither copper- nor MDA-modified LDLs are thought to be not 
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the primary modified LDL in vivo. Using LDL with various modifications other than 
oxidation as model antigens for atherosclerosis can greatly extend the scope and reach 
of future research. For example, LDL modified by cholesterylesterase (S. R. Han, et 
al., 2003), by lipoxygenase (Harats, et al., 2000), by myeloperoxidase (Malle, et al., 
2000), and by carbamylated LDL (Zeneng Wang, et al., 2007) all have been suggested 
to be atherogenic and more physiologically plausible than the conventional oxidation 
models of LDL.  
 
In summary, a broader range of autoantigens and autoantibodies can be used to 
develop an array of novel anti-ids, which could provide better prediction for 
atherosclerosis. More importantly, by studying the physiologically relevant epitopes, 
one can discover the pathologic mechanism of modified LDL. The key to this 
approach is a high throughput facility, for example microengraving technology 
(Ogunniyi, et al., 2009) and automated surface plasmon resonance system, to screen a 
larger number of hybridomas and phage clones. 
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7.5 Conclusions 
This thesis has provided a novel approach of establishing a standard assay for a range 
of atherosclerosis-related autoantigens, mainly OxLDL. The project has resulted in a 
novel surrogate of OxLDL which may mimic both the protein and the phospholipid 
components of the particle. The level of IgG antibodies against scFv H3 correlated 
inversely with the extent of LAD stenosis in the PARSEC samples. The true clinical 
utility of H3 assays, however, depends on further prospective validation. The 
potential dual peptide and phospholipid mimicking character of H3 may also provide 
many interesting potential applications for atherosclerosis research such as 
vaccination.  
 
Data obtained from the PARSEC cohort cannot answer conclusively the question of 
whether OxLDL antibodies are atherogenic or atheroprotective. Further future 
detailed classification of antibodies in patients can facilitate the identification of better 
biomarkers for specific populations. A more distant possibility could be to manipulate 
these molecules after having established causation. With regard to disease 
management, however, the only immunomodulation in atherosclerosis available at 
this time is to decrease the antigenic load either by life style modification or by 
medication (Kuiper, et al., 2007; G. Virella & Lopes-Virella, 2008).  
 
The generation of an array of anti-id from multiple autoantibodies against multiple 
atherosclerosis related antigens could lead to the discovery of more precise 
biomarkers. More importantly, by mapping the epitopes of relevant antigens (e.g., the 
putative dual mimetic site of scFv H3), one could delineate molecular mechanisms 
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involved in atherogenesis which could help researchers devise novel strategies for the 
prevention, diagnosis, slowing, treatment, and ultimately cure of atherosclerosis. This 
project has added additional understanding of the role that humoral immune system 
plays in atherosclerosis, and it has also provided a new toolbox to facilitate future 
research on atherosclerosis. 
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